<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1662-4548</issn><issn pub-type="epub">1662-453X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5100552</article-id><article-id pub-id-type="doi">10.3389/fnins.2016.00488</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Castillo</surname><given-names>Rolando I.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/373885/overview"/></contrib><contrib contrib-type="author"><name><surname>Rojo</surname><given-names>Leonel E.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/20911/overview"/></contrib><contrib contrib-type="author"><name><surname>Henriquez-Henriquez</surname><given-names>Marcela</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Hern&#x000e1;n</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/59286/overview"/></contrib><contrib contrib-type="author"><name><surname>Maturana</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Villar</surname><given-names>Mar&#x000ed;a J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fuentes</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gaspar</surname><given-names>Pablo A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/58973/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Translational Psychiatry Laboratory, Cl&#x000ed;nica Psiqui&#x000e1;trica Universitaria, Hospital Cl&#x000ed;nico Universidad de Chile</institution><country>Santiago, Chile</country></aff><aff id="aff2"><sup>2</sup><institution>Departamento de Biolog&#x000ed;a, Facultad de Qu&#x000ed;mica y Biolog&#x000ed;a, Universidad de Santiago de Chile</institution><country>Santiago, Chile</country></aff><aff id="aff3"><sup>3</sup><institution>Departamento de Laboratorios Cl&#x000ed;nicos, Escuela de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile</institution><country>Santiago, Chile</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Pediatrics, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University</institution><country>New York, NY, USA</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Pathology and Cell Biology, Columbia University</institution><country>New York, NY, USA</country></aff><aff id="aff6"><sup>6</sup><institution>Facultad de Medicina, Biomedical Neuroscience Institute, Universidad de Chile</institution><country>Santiago, Chile</country></aff><aff id="aff7"><sup>7</sup><institution>Departamento de Psiquiatr&#x000ed;a, Cl&#x000ed;nica Alemana</institution><country>Santiago, Chile</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Chao Deng, University of Wollongong, Australia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Alasdair Barr, University of British Columbia, Canada; Jessica Nealon, University of Wollongong, Australia</p></fn><corresp id="fn001">*Correspondence: Leonel E. Rojo <email xlink:type="simple">leonel.rojo@usach.cl</email>;<email xlink:type="simple">leonelrojoc@gmail.com</email></corresp><corresp id="fn002">Pablo A. Gaspar <email xlink:type="simple">pgaspar@neuro.med.uchile.cl</email>; <email xlink:type="simple">pabgaspar@uchile.cl</email></corresp><fn fn-type="other" id="fn003"><p>This article was submitted to Neuroendocrine Science, a section of the journal Frontiers in Neuroscience</p></fn></author-notes><pub-date pub-type="epub"><day>08</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>10</volume><elocation-id>488</elocation-id><history><date date-type="received"><day>14</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Castillo, Rojo, Henriquez-Henriquez, Silva, Maturana, Villar, Fuentes and Gaspar.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Castillo, Rojo, Henriquez-Henriquez, Silva, Maturana, Villar, Fuentes and Gaspar</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Metabolic syndrome (MS) is a prevalent and severe comorbidity observed in schizophrenia (SZ). The exact nature of this association is controversial and very often accredited to the effects of psychotropic medications and disease-induced life-style modifications, such as inactive lifestyle, poor dietary choices, and smoking. However, drug therapy and disease-induced lifestyle factors are likely not the only factors contributing to the observed converging nature of these conditions, since an increased prevalence of MS is also observed in first episode and drug-na&#x000ef;ve psychosis populations. MS and SZ share common intrinsic susceptibility factors and etiopathogenic mechanisms, which may change the way we approach clinical management of SZ patients. Among the most relevant common pathogenic pathways of SZ and MS are alterations in the sphingolipids (SLs) metabolism and SLs homeostasis. SLs have important structural functions as they participate in the formation of membrane &#x0201c;lipid rafts.&#x0201d; SLs also play physiological roles in cell differentiation, proliferation, and inflammatory processes, which might be part of MS/SZ common pathophysiological processes. In this article we review a plausible mechanism to explain the link between MS and SZ through a disruption in SL homeostasis. Additionally, we provide insights on how this hypothesis can lead to the developing of new diagnostic/therapeutic technologies for SZ patients.</p></abstract><kwd-group><kwd>metabolic syndrome</kwd><kwd>psychosis</kwd><kwd>schizophrenia</kwd><kwd>sphingolipids</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica<named-content content-type="fundref-id">10.13039/501100002848</named-content></funding-source></award-group><award-group><funding-source id="cn002">Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico<named-content content-type="fundref-id">10.13039/501100002850</named-content></funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><equation-count count="0"/><ref-count count="137"/><page-count count="15"/><word-count count="10072"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Schizophrenia (SZ) is a severe and chronic psychotic disorder with a lifetime risk of 0.7% (Saha et al., <xref rid="B98" ref-type="bibr">2005</xref>), in which genetic and environmental factors contribute to abnormal anatomical and functional connectivity of the brain (Stephan et al., <xref rid="B113" ref-type="bibr">2006</xref>; Canu et al., <xref rid="B16" ref-type="bibr">2015</xref>). Abnormal connectivity may be the underlying contributor to a wide range of symptoms observed in this disease, such as hallucinations, delusions, avolition, blunted affect, and cognitive dysfunctions (Gaspar et al., <xref rid="B37" ref-type="bibr">2012</xref>). These symptoms often cause poor functional outcome, frequent co-morbidities, and increased mortality rate. For these reasons, SZ is ranked among the top 10 leading causes of disease-related disability in the world and is consistently demonstrated to have a major negative impact on quality of life (WHO, <xref rid="B128" ref-type="bibr">2001</xref>).</p><p>The well-known association between SZ and metabolic syndrome (MS) may be a contributor to the poor long-term outcomes stated above. The prevalence of MS among medicated SZ patients is as high as 60%, compared to 30% in the general population (Malhotra et al., <xref rid="B76" ref-type="bibr">2013</xref>; Papanastasiou, <xref rid="B89" ref-type="bibr">2013</xref>) with the subsequent increment in cardiovascular morbi-mortality. The nature of this association has been frequently accredited to the adverse effects of psychotropic medications, especially second-generation antipsychotics (Jin et al., <xref rid="B63" ref-type="bibr">2004</xref>; Peet, <xref rid="B92" ref-type="bibr">2004</xref>; Filakovi&#x00107; et al., <xref rid="B33" ref-type="bibr">2012</xref>), and to disease-induced life-style modifications, such as inactive lifestyle, unhealthy diet and smoking (Peet, <xref rid="B92" ref-type="bibr">2004</xref>). However, several studies have shown that increased insulin levels and glucose abnormalities can occur at early stages of the disease, in drug na&#x000ef;ve first episode psychosis patients (Ryan et al., <xref rid="B97" ref-type="bibr">2003</xref>; Spelman et al., <xref rid="B111" ref-type="bibr">2007</xref>; Fernandez-Egea et al., <xref rid="B30" ref-type="bibr">2009</xref>; Verma et al., <xref rid="B126" ref-type="bibr">2009</xref>; Guest et al., <xref rid="B44" ref-type="bibr">2010</xref>; Chadda et al., <xref rid="B18" ref-type="bibr">2013</xref>) and in their first-degree relatives (Fernandez-Egea et al., <xref rid="B31" ref-type="bibr">2008a</xref>,<xref rid="B32" ref-type="bibr">b</xref>). It is difficult to control for all the risk factors associated to MS (e.g., poor diet, lack of exercise, cigarette smoking, environmental stress, and drug abuse) in observational clinical studies of SZ patients, and indeed most studies often fail to properly control for all of these factors. However, the study of Fernandez-Egea et al., matched the groups by age, sex, heart rate, body mass index, tobacco consumption, and ethnic origin (Fernandez-Egea et al., <xref rid="B30" ref-type="bibr">2009</xref>) demonstrating the plausibility of a predisposition for developing MS among SZ patients and their close relatives. This brings the testable hypothesis that MS in SZ patients would not only be linked to epigenetic factors, but also to genetic alterations, such as polymorphisms of enzymes and/or receptors involved in brain physiology (Yogaratnam et al., <xref rid="B134" ref-type="bibr">2013</xref>).</p><p>Although there is evidence for the association of SZ with some MS associated genes like methylenetetrahydrofolate reductase (MTHFR) (Ellingrod et al., <xref rid="B28" ref-type="bibr">2008</xref>) and alpha-1A adrenergic receptor (ADRA1A) (Cheng et al., <xref rid="B21" ref-type="bibr">2012</xref>), none of these associations have led to a common metabolic pathway, which actually links MS with SZ providing the rationale for research toward a &#x0201c;drugable&#x0201d; therapeutic/prophylactic target. In this context, it is of utmost importance to identify common molecular pathways that explain this association in order to improve current diagnostic and therapeutic strategies and to avoid major metabolic complications.</p><p>Despite the fact that most of the current research on SZ has been focused on the role of synaptic proteins as etiopathogenic mediators of the disease (Stephan et al., <xref rid="B114" ref-type="bibr">2009</xref>; Seshadri et al., <xref rid="B106" ref-type="bibr">2013</xref>), the interest in membrane lipids (Horrobin, <xref rid="B55" ref-type="bibr">1998</xref>), and specifically sphingolipids (SLs), has increased during the last decade (Schwarz et al., <xref rid="B105" ref-type="bibr">2008</xref>; Narayan et al., <xref rid="B84" ref-type="bibr">2009</xref>). Moreover, cumulative evidence suggests that SLs may link MS (Cowart, <xref rid="B24" ref-type="bibr">2008</xref>) to psychotic disorders (Narayan and Thomas, <xref rid="B85" ref-type="bibr">2011</xref>). Thus, SLs seemingly are interesting putative candidates for common etiopathogenic mediators of these disorders.</p><p>In this review we analyze the relevance of SLs in the MS associated with SZ, and we also highlight molecular events linking SZ with MS, in order to explain common etiopathogenic mechanisms and the predisposition of SZ patients to develop metabolic complications. Finally, according to our perspective, we propose a unifying, testable hypothesis to explain the participation of SLs in MS and SZ and also putative diagnostic/therapeutic applications, based on the detection of sub-families of SLs in peripheral samples of SZ patients.</p></sec><sec id="s2"><title>General aspects of sphingolipids</title><p>SLs encompass a wide and complex family of membrane lipids in which a fatty acid is linked to a long sphingosine carbon backbone via an amide bond. Depending on their hydrophilic attachments, they can be divided into three main types of SLs: ceramides, sphingomyelins (SMs), and glycosphingolipids (GSLs) (Figure <xref ref-type="fig" rid="F1">1</xref>). The mammalian SLs metabolism has three major metabolic pathways: the <italic>de novo</italic> pathway coming from saturated fatty acids, the salvage pathway, and the SMs pathway, all of which converge in ceramides. The heterogeneous and complex GSLs are synthesized from ceramides (Figure <xref ref-type="fig" rid="F2">2</xref>). Due to their amphipathic properties, SLs are major components in cell membranes and are especially ubiquitous in the central nervous system (CNS) membrane &#x0201c;lipid rafts&#x0201d;(Colombaioni and Garcia-Gil, <xref rid="B22" ref-type="bibr">2004</xref>; Aureli et al., <xref rid="B7" ref-type="bibr">2015</xref>). Since their discovery in 1884, SLs have been shown to be involved in several neuropsychiatric (Kolter and Sandhoff, <xref rid="B69" ref-type="bibr">2006</xref>; Adibhatla and Hatcher, <xref rid="B2" ref-type="bibr">2008</xref>; Haughey, <xref rid="B49" ref-type="bibr">2010</xref>), metabolic, immune, oncogenic, and inflammatory disorders (Lahari and Futerman, <xref rid="B72" ref-type="bibr">2007</xref>; Zeidan and Hannun, <xref rid="B135" ref-type="bibr">2007</xref>). Today it is widely accepted that the biophysical and signaling properties of SLs allow them to participate in the regulation of several key cellular processes, such as membrane microdomains organization, allosteric modulation of membrane proteins, and cell to cell interaction, differentiation, proliferation, inflammation, and apoptosis (Hannun and Obeid, <xref rid="B47" ref-type="bibr">2008</xref>). In fact, SLs participate in several neuronal and metabolic processes, making them crucial to the normal and pathological functioning of these tissues.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>General sphingolipid structure</bold>. Sphingolipids are composed of a sphingosine backbone linked to a fatty acid via an amide bond. There are three main types of sphingolipids, which differ in their hydrophilic attachments: ceramides, sphingomyelins, and glycosphingolipids.</p></caption><graphic xlink:href="fnins-10-00488-g0001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Pathways of sphingolipid metabolism</bold>. Sphingolipids have three major metabolic pathways: the <italic>de novo</italic> pathway coming from saturated fatty acids, the salvage pathway and the sphingomyelin pathway, all of which converge in ceramides.</p></caption><graphic xlink:href="fnins-10-00488-g0002"/></fig></sec><sec id="s3"><title>Metabolic syndrome and sphingolipids</title><sec><title>Metabolic syndrome pathophysiology</title><p>MS represents a cluster of cardiovascular risk factors including glucose intolerance, atherogenic dyslipidemia, and hypertension, leading to an increased risk of cardiovascular morbidity and mortality (Isomaa et al., <xref rid="B57" ref-type="bibr">2001</xref>). MS shows a tight association with central (or visceral) fat mass, which is a good predictor of severity for cardiovascular complications compared to peripheral fat mass (Matsuzawa et al., <xref rid="B78" ref-type="bibr">2011</xref>). This is because central fat mass is a major source of active biomolecules, like adipokines, cytokines, and free fatty acids (FFAs), which promote a chronic pathological status of inflammation and oxidative stress (Holland et al., <xref rid="B53" ref-type="bibr">2007</xref>; Kaur, <xref rid="B67" ref-type="bibr">2014</xref>). Several molecular pathways have been studied to understand the events linking central fat mass, FFAs and MS (Holland et al., <xref rid="B53" ref-type="bibr">2007</xref>), but current data do not yet provide compelling answers. In this context, emerging evidence demonstrates that overnutrition induces SLs synthesis and turnover, which in turn &#x0201c;remodels&#x0201d; SLs profiles and their topological distribution.</p><p>A plausible explanation for this is that overnutrition and visceral obesity change FFAs profile, principally elevating levels of saturated fatty acids (SFAs) (Holland and Summers, <xref rid="B54" ref-type="bibr">2008</xref>; Heilbronn et al., <xref rid="B51" ref-type="bibr">2013</xref>; Kaur, <xref rid="B67" ref-type="bibr">2014</xref>). These molecules promote ceramides synthesis through the production of palmitate-CoA and acyl-CoA, SFAs-derivatives involved in the <italic>de novo</italic> and salvage pathway of SLs metabolism, respectively (Figure <xref ref-type="fig" rid="F2">2</xref>). Palmitate-CoA is a substrate for palmitoyltransferase, the rate limiting enzyme of the <italic>de novo</italic> synthesis pathway of ceramides, and it stimulates palmitoyltransferase in a concentration-dependent manner. On the other hand, acyl-CoA can increase ceramides synthesis as a substrate of ceramides synthase (CerS) in the salvage pathway (Figure <xref ref-type="fig" rid="F2">2</xref>; Merrill et al., <xref rid="B79" ref-type="bibr">1988</xref>). These metabolic changes increase ceramides levels, which in turn modify intracellular signaling and promote MS-associated conditions, like atherothrombotic status and glucose intolerance (Cowart, <xref rid="B24" ref-type="bibr">2008</xref>).</p></sec><sec><title>Sphingolipids and alterations of the glucose metabolism</title><p>The current literature shows that certain SLs can impair glucose metabolism in different organs, including pancreatic, skeletal muscle, and adipose tissues.</p><p>In pancreatic islets, lipid oversupply increases the ceramides &#x003b2;-cell induced apoptosis (or &#x0201c;lipoapoptosis&#x0201d;) (Shimabukuro et al., <xref rid="B108" ref-type="bibr">1998b</xref>; Unger and Orci, <xref rid="B123" ref-type="bibr">2002</xref>) In fact, pharmacological inhibitors of the ceramides biosynthesis ameliorate the lipotoxic effect on pancreatic &#x003b2;-cells (Shimabukuro et al., <xref rid="B107" ref-type="bibr">1998a</xref>). Interestingly, ceramides also inhibit the expression of pro-insulin genes through the activation of c-Jun N-terminal kinases (JNK), an inhibitor of kappa B kinase beta (I&#x003ba;K&#x003b2;) (Summers, <xref rid="B118" ref-type="bibr">2006</xref>). Both mechanisms decrease pancreatic insulin secretion.</p><p>Ceramides also contribute to the glucose-resistance phenotype in the skeletal muscle. Here, ceramides impair glucose caption by the inhibition of the kinase B (Akt/PKB) insulin signaling pathway (Chavez et al., <xref rid="B20" ref-type="bibr">2003</xref>). This is effect is achieved through protein phosphatase 2 (PP2A) (Zinda et al., <xref rid="B136" ref-type="bibr">2001</xref>) or protein kinase C zeta (PKC&#x003b6;) dependent mechanisms (Bourbon et al., <xref rid="B13" ref-type="bibr">2002</xref>) and also by the inhibition of Akt translocation to the plasma membrane (Stratford et al., <xref rid="B116" ref-type="bibr">2001</xref>). Notably, <italic>in vivo</italic> studies on insulin resistant obese patients showed increased ceramides levels in muscle biopsies (Adams et al., <xref rid="B1" ref-type="bibr">2004</xref>; Straczkowski et al., <xref rid="B115" ref-type="bibr">2007</xref>) and newly discovered evidence has identified C16:0-ceramide as the principal mediator of obesity-related insulin resistance (Hla and Kolesnick, <xref rid="B52" ref-type="bibr">2014</xref>; Raichur et al., <xref rid="B95" ref-type="bibr">2014</xref>; Turpin et al., <xref rid="B121" ref-type="bibr">2014</xref>).</p><p>Finally, ceramides display other pro-inflammatory properties, inducing inflammation in adipose tissue via tumor necrosis factor &#x003b1; (TNF&#x003b1;) signaling (Bikman, <xref rid="B11" ref-type="bibr">2012</xref>; Maceyka and Spiegel, <xref rid="B74" ref-type="bibr">2014</xref>). TNF&#x003b1; induces insulin resistance by direct down-regulation of the insulin-regulatable glucose transporter type 4 (GLUT-4). TNF&#x003b1; also acts indirectly on the glucose uptake, by inducing the up-regulation of ganglioside GM3, which is a member of the SLs family that has proven to inhibit both: the insulin-mediated activation of insulin receptor substrate-1 (IRS-1) (Tagami et al., <xref rid="B119" ref-type="bibr">2002</xref>) and the expression of insulin receptors from the lipid rafts (Kabayama et al., <xref rid="B64" ref-type="bibr">2005</xref>). In sum, SLs can interrupt the insulin signaling pathway in at least four different forms (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Relationship between visceral obesity, sphingolipids, and metabolic abnormalities</bold>. Saturated fatty acids are included in the sphingolipid pathways and are synthesized to ceramides. Ceramides affect the insulin signaling pathway and favor the atherothrombotic process through different metabolic pathways.</p></caption><graphic xlink:href="fnins-10-00488-g0003"/></fig></sec><sec><title>Sphingolipids and atherothrombosis</title><p>It is important to mention that SLs synthesis is necessary for the activation and subsequent regulation of the sterol regulatory element-binding proteins (SREBPs), which are key transcription factors in the lipid biosynthesis that regulate the transcription of enzymes involved in the synthesis of cholesterol, phospholipids, and fatty acids (Worgall et al., <xref rid="B131" ref-type="bibr">2002</xref>; Worgall, <xref rid="B130" ref-type="bibr">2008</xref>). Ceramides and SMs are also implicated in the regulation of cholesterol efflux by a mechanism that involves the cholesterol-efflux receptors ABCA1 and ABCG1. Thus, the ABCG1-mediated efflux of cholesterol is dependent on the cellular SM level in the plasma membrane, which implies that SM influences the high-density lipoproteins (HDL) plasma levels (Kaminski et al., <xref rid="B66" ref-type="bibr">2006</xref>; Kobayashi et al., <xref rid="B68" ref-type="bibr">2006</xref>; Sano et al., <xref rid="B100" ref-type="bibr">2007</xref>).</p><p>Increased levels of ceramides seem to be related to the aggregation of low density lipoprotein (LDL) particles within the arterial wall, as aggregated LDL particles from atherosclerotic lesions (Guyton and Klemp, <xref rid="B45" ref-type="bibr">1996</xref>) have 10- to 50-fold higher levels of ceramides than plasmatic LDL particles (Schissel et al., <xref rid="B103" ref-type="bibr">1996</xref>). Moreover, ceramides have been shown to induce apoptosis of cells lining the vascular wall, a process implicated in plaque rupture of atherothrombotic disease (Mallat and Tedgui, <xref rid="B77" ref-type="bibr">2001</xref>).</p><p>In parallel, S1P stimulates the proliferation of endothelial and smooth muscle cells in the vascular walls, promoting vascular remodeling and plaque thickening. Finally, ceramides and S1P increase plasminogen activator inhibitor-1 (PAI-1), an inhibitor of fibrinolysis (Soeda et al., <xref rid="B110" ref-type="bibr">1995</xref>; Ito et al., <xref rid="B58" ref-type="bibr">2013</xref>), favoring platelet activation and aggregation (Bhatia et al., <xref rid="B10" ref-type="bibr">2004</xref>). Taken together, this evidence strongly suggests that SLs, and specifically ceramides, are crucial in the pathophysiology of the atherothrombotic process and cardiovascular events in obese, overfed, or malnourished patients (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><p>Interestingly, obesity and alterations of the lipid metabolism have also been associated with psychotic disorders (Oresic, <xref rid="B88" ref-type="bibr">2012</xref>). This topic will be reviewed in the next section.</p></sec></sec><sec id="s4"><title>Healthy central nervous system and sphingolipids</title><p>Lipids in the brain account for 60% of its dry weight (Horrobin, <xref rid="B55" ref-type="bibr">1998</xref>), and SLs in particular are found in high concentrations in the membranes of neurons and oligodendrocytes (van Echten-Deckert and Herget, <xref rid="B124" ref-type="bibr">2006</xref>; Piccinini et al., <xref rid="B93" ref-type="bibr">2010</xref>). This peculiar lipid composition and concentration favors the organization of laterally organized lipid-driven membrane domains. In fact, SLs have functional properties in inflammatory responses, and also structural properties as precursors of SMs and GSLs, which are necessary for the formation of the specialized membrane &#x0201c;lipid rafts&#x0201d; in neurons and oligodendrocytes myelin sheaths (Aureli et al., <xref rid="B7" ref-type="bibr">2015</xref>). Lipid rafts are important for cell-to-cell interactions and modulation of membrane-associated proteins which determine normal synaptic neurotransmission (Allen et al., <xref rid="B3" ref-type="bibr">2007</xref>) and axon-myelin stability and communication (Aureli et al., <xref rid="B7" ref-type="bibr">2015</xref>). Due to these biologically critical features, SLs are a vital factor in the normal functioning of neurons and oligodendrocytes, determining appropriate axonal/synaptic connectivity, and neuronal survival (Posse de Chaves, <xref rid="B94" ref-type="bibr">2006</xref>). In fact, the absence of the complex GSL synthesis function during early neurodevelopment stages is lethal in animal models (Jennemann et al., <xref rid="B62" ref-type="bibr">2005</xref>).</p></sec><sec id="s5"><title>Schizophrenia pathophysiology</title><p>SZ is assumed to be a neurodevelopmental disorder in which genetic and environmental factors contribute to abnormal neuronal (Stephan et al., <xref rid="B113" ref-type="bibr">2006</xref>; Kahn and Sommer, <xref rid="B65" ref-type="bibr">2015</xref>) and glial cell (Hakak et al., <xref rid="B46" ref-type="bibr">2001</xref>; Tkachev et al., <xref rid="B120" ref-type="bibr">2003</xref>; Goudriaan et al., <xref rid="B43" ref-type="bibr">2014</xref>; Bernstein et al., <xref rid="B9" ref-type="bibr">2015</xref>) histology and function, leading to specific white matter and synaptic abnormalities that impair anatomical and functional brain connectivity.</p><p>Although the initial SZ pathognomonic events are unknown, a plausible inflammatory hypothesis states that environmental stress during early childhood (e.g., perinatal infections)&#x02014;on top of increased genetic vulnerability&#x02014;may stimulate the immune system to secrete pro-inflammatory cytokines contributing to subclinical but long-lasting neurotoxic processes. Current evidence supports the hypothesis that chronic inflammation impairs the monoaminergic and glutamatergic normal neurotransmission and damages white and gray matter structures in SZ patients (M&#x000fc;ller et al., <xref rid="B82" ref-type="bibr">2015</xref>; Najjar and Pearlman, <xref rid="B83" ref-type="bibr">2015</xref>).</p><p>In fact, neuropathological studies in brains of SZ patients have shown that neuronal density increases, but glial density and dendritic spines decreases (Davis et al., <xref rid="B25" ref-type="bibr">2003</xref>; Garver et al., <xref rid="B36" ref-type="bibr">2008</xref>; Kyriakopoulos et al., <xref rid="B71" ref-type="bibr">2008</xref>; Bakhshi and Chance, <xref rid="B8" ref-type="bibr">2015</xref>; Gong et al., <xref rid="B41" ref-type="bibr">2016</xref>). Other studies have also demonstrated that SZ brains display alterations in the expression of presynaptic proteins (e.g., increased SNARE interactions) and in the oligodendrocyte myelin sheet lamella (Bakhshi and Chance, <xref rid="B8" ref-type="bibr">2015</xref>; Ramos-Miguel et al., <xref rid="B96" ref-type="bibr">2015</xref>). There is also evidence of reduced brain weight and volume in a various brain regions, along with cerebral ventricular enlargement, loss of cerebral asymmetry, and reduction of fronto-temporal white matter tracts, all of which would impair structural connectivity of the brain (Stephan et al., <xref rid="B113" ref-type="bibr">2006</xref>; Canu et al., <xref rid="B16" ref-type="bibr">2015</xref>). Although there are other plausible hypotheses to explain the functional brain disconnection in SZ, we highlight a convergent hypothesis that explains the functional consequences of these heterogeneous synaptic and axonal anomalies based on the hypofunction of N-methyl-D-aspartate (NMDA) receptors in parvalbumin-positive &#x003b3;-aminobutyric acid (GABA)-ergic interneurons. This abnormal NMDA signaling could lead to the disruption of the cortical tuning of glutamatergic pyramidal neurons. This hypofunction would cause a disengagement of the cortico-cortical and cortico-subcortical networks, impairing the functional connectivity of different brain areas (Ford et al., <xref rid="B35" ref-type="bibr">2007</xref>; Gaspar et al., <xref rid="B38" ref-type="bibr">2009</xref>, <xref rid="B37" ref-type="bibr">2012</xref>; Uhlhaas and Singer, <xref rid="B122" ref-type="bibr">2010</xref>; Gonzalez-Burgos and Lewis, <xref rid="B42" ref-type="bibr">2012</xref>; Woodward et al., <xref rid="B129" ref-type="bibr">2012</xref>; Cao et al., <xref rid="B17" ref-type="bibr">2016</xref>).</p><p>Thus, inflammation and the loss of normal axonal or synaptic connectivity are seemingly responsible for the cognitive impairments and other classical symptoms (hallucinations, delusions, negative, and affective symptoms) observed in this disease, leading to the major social difficulties seen in these patients.</p></sec><sec id="s6"><title>Schizophrenia and sphingolipids</title><p>Numerous studies have shown alterations of the membrane lipid composition (Horrobin, <xref rid="B55" ref-type="bibr">1998</xref>) and SLs metabolism in SZ (Yao et al., <xref rid="B132" ref-type="bibr">2000</xref>; Schwarz et al., <xref rid="B105" ref-type="bibr">2008</xref>; Narayan et al., <xref rid="B84" ref-type="bibr">2009</xref>; Smesny et al., <xref rid="B109" ref-type="bibr">2013</xref>) and other neuropsychiatric diseases (Posse de Chaves, <xref rid="B94" ref-type="bibr">2006</xref>; Adibhatla and Hatcher, <xref rid="B2" ref-type="bibr">2008</xref>; Jana et al., <xref rid="B60" ref-type="bibr">2009</xref>; Kornhuber et al., <xref rid="B70" ref-type="bibr">2009</xref>; Haughey, <xref rid="B49" ref-type="bibr">2010</xref>; Mielke et al., <xref rid="B80" ref-type="bibr">2010</xref>; Narayan and Thomas, <xref rid="B85" ref-type="bibr">2011</xref>; M&#x000fc;hle et al., <xref rid="B81" ref-type="bibr">2013</xref>; Saito and Saito, <xref rid="B99" ref-type="bibr">2013</xref>). Due to their functional and structural roles, SLs could explain in part the inflammatory, synaptic and white matter changes that leads to disconnectivity in SZ (Jana et al., <xref rid="B60" ref-type="bibr">2009</xref>; Please see Boxes <xref ref-type="boxed-text" rid="Box1">1</xref>, <xref ref-type="boxed-text" rid="Box2">2</xref> for further discussion of SL abnormalities and their distribution across the central nervous system). Here we discuss how the clinical data and several model systems provide evidence on the abnormal metabolism of SLs and its close connections with neuroinflammation and disconnectivity in SZ.</p><boxed-text id="Box1" position="float"><label>Box 1</label><caption><title>Sphingolipid abnormalities in specific brain areas.</title></caption><p>Despite the fact that SLs-related neuropathological alterations have been linked to specific brain areas (e.g., prefrontal Cortex or thalamus), it is still difficult to reach coherent conclusions that can help to further understand this conundrum, if we are only based on the expression profiles of SLs-related enzymes. For instance, it is known that the six ceramide synthase (CerS) subtypes are differentially expressed through the nervous system. CerS determine the acyl-chain length of SLs, thus each tissue/cell has distinct SL acyl-chain length profiles. As an example, in the brain, CerS1 (which targets C18 acyl-chains) is distributed primarily in neurons, whereas CerS2, responsible for the synthesis of C22-C24 acyl-chain SLs, is expressed specifically in oligodendrocytes and Schwann cells. Several studies suggest that SLs with defined acyl-chain lengths play distinct pathophysiological roles in disease models (Park et al., <xref rid="B90" ref-type="bibr">2014</xref>; Park and Park, <xref rid="B91" ref-type="bibr">2015</xref>) and the alterations in the relative balance of these species might be of pathogenic relevance in SZ.</p></boxed-text><boxed-text id="Box2" position="float"><label>Box 2</label><caption><title>Sphingolipid abnormalities in the peripheral nervous system.</title></caption><p>If SZ patients suffer from a genetic SLs metabolism vulnerability, we should also expect peripheral neurologic abnormalities that go far beyond central nervous system dysfunctions. In fact, there is evidence of abnormal peripheral neuromuscular functioning in SZ patients, which supports the idea of SZ as a generalized disease rather than a specific central nervous system problem. For instance, there are alterations of the &#x003b1;-motoneuron excitability, increased motor unit fiber densities and increased branching of terminal motor nerves to elevated levels of muscular enzymes (Flyckt et al., <xref rid="B34" ref-type="bibr">2000</xref>). Moreover, there is electrophysiological evidence on the functional consequences of these abnormalities showing impaired peripheral impulse propagation in electromyographic recordings (Borg et al., <xref rid="B12" ref-type="bibr">1987</xref>). All of these findings are compatible with membrane defects.</p></boxed-text><sec><title>Sphingolipids and schizophrenia inflammatory hypothesis</title><p>Some SLs have pro-inflammatory properties (Maceyka and Spiegel, <xref rid="B74" ref-type="bibr">2014</xref>) that can be involved in the initiation and maintenance of the subclinical inflammatory status linked to the above mentioned &#x0201c;neurodevelopmental vulnerability-stress-inflammatory model of SZ&#x0201d; (M&#x000fc;ller et al., <xref rid="B82" ref-type="bibr">2015</xref>). Moreover, SLs have also pro-apoptotic properties which suggest a plausible neurodegenerative component of SZ. Although SZ is not classified as a neurodegenerative disorder, it is clear that the progressive deterioration of some SZ subjects derives from incomplete apoptotic mechanisms at the local synaptic level (without inducing immediate neuronal death; Jarskog et al., <xref rid="B61" ref-type="bibr">2005</xref>). Thus, SLs may be involved in both: pro-inflammatory and pro-apoptotic pathways.</p><p>In agreement with these plausible mechanisms, postmortem studies have found a significant decrease of phosphatidylcholine (PC) in the white matter of SZ patients (Yao et al., <xref rid="B132" ref-type="bibr">2000</xref>). PC is the choline donor to SMs in neurons and oligodendrocytes. Therefore, low levels of PC are related to decreased SMs levels and, eventually, increased turnover of SMs to ceramides (Posse de Chaves, <xref rid="B94" ref-type="bibr">2006</xref>). These findings may be associated with oligodendrocyte dysfunction, since SMs is a major component of myelin sheaths and ceramides have an apoptotic and inflammatory role.</p><p>Neuropathological evidence shows increased levels of phosphatidylserine in the left thalamic gray matter of SZ patients (Schmitt et al., <xref rid="B104" ref-type="bibr">2004</xref>). This suggests the presence of a ceramides-mediated cell death, because phosphatidylserine acts as a potent activator of neutral sphingomyelinase (Sawai and Hannun, <xref rid="B102" ref-type="bibr">1999</xref>) and stimulates phagocytosis of apoptotic cells (Chang et al., <xref rid="B19" ref-type="bibr">2000</xref>).</p><p>Consistent with the previous findings, bipolar disorder, and SZ patients are reported to show significantly increased levels of ceramides and decreased levels of PC in their white matter, regardless of antipsychotic treatment (Schwarz et al., <xref rid="B105" ref-type="bibr">2008</xref>). Remarkably, environmental stress (such as psychoactive substances and oxidative stress) that are known to be involved in the development of several psychiatric disorders, also activate sphingomyelinase, increasing pro-inflammatory metabolites like ceramides and its derivatives (Posse de Chaves, <xref rid="B94" ref-type="bibr">2006</xref>; Jana et al., <xref rid="B60" ref-type="bibr">2009</xref>; M&#x000fc;hle et al., <xref rid="B81" ref-type="bibr">2013</xref>) (Figure <xref ref-type="fig" rid="F4">4</xref>).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Relationship between sphingolipids and schizophrenia</bold>. There are at least three different described ways by which abnormal sphingolipid metabolism could impair normal neural functioning in humans: (1) By abnormal expression of galactosylceramide synthase increasing ceramides and decreasing galactosylceramides in myelin sheaths. (2) Stimulation of sphingomyelinase by stress factors, leading to a breakdown of sphingomyelins to ceramides. (3) And finally, by decreased synthesis of phosphatidylcholine. All of these mechanisms impact normal lipid membrane properties and might induce the synaptic and axonal disconnectivity seen in schizophrenia.</p></caption><graphic xlink:href="fnins-10-00488-g0004"/></fig></sec><sec><title>Sphingolipids and the schizophrenia disconnectivity hypothesis</title><p>Genetic studies in humans and animals provide additional evidence for the role of abnormal SLs metabolism in the SZ disconnectivity hypothesis. Genes related to the metabolism of some structural SLs, such as SMs and GSLs, are altered in subjects with SZ, which might impair normal neuronal or glial function. The article of Narayan et al. is of particular interest in this context, as it shows decreased expression of UGT8-encoding for galactosyltransferase (CGT) and GAL3ST1&#x02013;encoding for cerebroside sulfotransferase (CST) in these subjects. CGT is responsible for converting ceramides to galactosylceramides, and CST is responsible for the further metabolization of galactosylceramides to sulfatides. Diminished expression of these two genes may result in the overall decreased levels of galactosylceramides and sulfatides, which are major lipid components of the oligodendrocyte myelin sheath (Narayan et al., <xref rid="B84" ref-type="bibr">2009</xref>) (Figure <xref ref-type="fig" rid="F4">4</xref>).</p><p>Interestingly, investigations with animal models confirm the <italic>in vivo</italic> consequences of these GSL pathologies. In fact, mice lacking CGT form unstable and functionally affected myelin and exhibit progressive demyelination, accompanied by severe motor coordination deficits (Z&#x000f6;ller et al., <xref rid="B137" ref-type="bibr">2005</xref>). Another study shows that the administration of GM1 ganglioside fully restored the mice's MK801-SZ cognitive model, correcting cognitive deficits and the impaired BDNF signaling (Ni et al., <xref rid="B87" ref-type="bibr">2016</xref>). Finally, there is evidence that the induction of catalytically inactive SLs enzymes induces cognitive and behavioral abnormalities. For example, some inactive CerS-specific subtypes induce myelin sheath GSLs and glycoprotein defects, as well as behavioral abnormalities that include motor, exploration and habituation deficits (Imgrund et al., <xref rid="B56" ref-type="bibr">2009</xref>; Ginkel et al., <xref rid="B39" ref-type="bibr">2012</xref>; Ebel et al., <xref rid="B27" ref-type="bibr">2013</xref>). Perhaps findings observed in first-episode SZ patients with lower levels of ceramide 1 (a long chain ceramide) and higher levels of ceramides 5 and 8 (short chain ceramides) may be explained in this context (Smesny et al., <xref rid="B109" ref-type="bibr">2013</xref>).</p><p>One potential explanation for these behavioral consequences is a membrane microdomain destabilization due to a lack of structural SLs. As suggested above, membrane &#x0201c;lipid rafts&#x0201d; are mostly formed and regulated by SLs. This is important for axonal-glial (Figure <xref ref-type="fig" rid="F5">5</xref>) and synaptic interactions, both crucial for proper brain connectivity (Jackman et al., <xref rid="B59" ref-type="bibr">2009</xref>). In this context, the study by Col&#x000f3;n-S&#x000e1;ez and Yakel reported that the enzymatic hydrolysis of SMs in rat hippocampal neurons alters the &#x003b1;-7 nicotinic acetylcholine receptor function, presumably influencing its anchoring in the lipid rafts (Col&#x000f3;n-S&#x000e1;ez and Yakel, <xref rid="B23" ref-type="bibr">2011</xref>).</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Schematic representation of the participation of membrane glycosphingolipid-enriched microdomains in schizophrenia</bold>. The repartitioning of molecules into (or out of) lipid rafts can lead to an impaired myelin structure in oligodendrocytes and impaired synaptic connectivity in neurons. In this example, oligodendrocytes myelin-associated glycoprotein (MAG) and myelin/oligodendrocyte glycoprotein (MOG) are segregated from the lipid raft following a structural sphingolipid abnormality, leading to an insufficient axonal-glial interaction and loss of brain connectivity.</p></caption><graphic xlink:href="fnins-10-00488-g0005"/></fig><p>Overall, the discussed evidence supports the hypothesis that SZ disconnectivity can be explained by alterations in membrane SLs metabolism, which lead to a decreased axonal myelination and impaired synaptic plasticity (Figure <xref ref-type="fig" rid="F5">5</xref>).</p></sec><sec><title>Future of sphingolipids in the development of new diagnostic and therapeutic technologies for schizophrenia-related metabolic syndrome</title><p>For a long time, clinicians have speculated about the potential options to exert therapeutic interventions during the early stages of SZ, with the goal of delaying or averting the illness and/or its complications (Sullivan, <xref rid="B117" ref-type="bibr">1994</xref>; Srihari et al., <xref rid="B112" ref-type="bibr">2013</xref>). However, effective early interventions require the ability to correctly identify the patients that will have a poor clinical course and more comorbid conditions, like MS.</p><p>Even though international clinical guidelines recommend undertaking a complete cardiovascular risk assessment in first episode psychosis patients before pharmacological treatment is initiated (De-Hert et al., <xref rid="B26" ref-type="bibr">2009</xref>), the routine metabolic screening at early stages does not consider a MS genetic vulnerability. In fact, we do not have clinically validated biomarkers for the diagnosis or follow up of SZ, nor its metabolic complications (Weickert et al., <xref rid="B127" ref-type="bibr">2013</xref>). Thus, it is still a challenge to select a particular subpopulation of SZ patients to follow.</p><p>Emerging evidence suggests that SLs may be suitable biomarkers for MS, revealing important associations between MS and the level of certain SLs in peripheral blood samples. There are at least six studies that show elevated levels of ceramides or GM3 gangliosides in overfed, overweight or diabetic/dyslipidemic patients in peripheral samples. Additionally, these abnormalities are usually correlated with elevation in other parameters, such as adiponectin, cholesterol, TNF&#x003b1; and glucose (Sato et al., <xref rid="B101" ref-type="bibr">2008</xref>; Majumdar and Mastrandrea, <xref rid="B75" ref-type="bibr">2012</xref>; Heilbronn et al., <xref rid="B51" ref-type="bibr">2013</xref>; Lopez et al., <xref rid="B73" ref-type="bibr">2013</xref>; Ng et al., <xref rid="B86" ref-type="bibr">2015</xref>; Veillon et al., <xref rid="B125" ref-type="bibr">2015</xref>) (Table <xref ref-type="table" rid="T1">1</xref>). These results are paralleled by similar findings in an overfed and diabetic primate model (Brozinick et al., <xref rid="B15" ref-type="bibr">2013</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Sphingolipids, and other related lipids in peripheral samples as biomarkers of schizophrenia or metabolic syndrome in humans</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>N</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Subjects</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Gender</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Age</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Sample</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Main Findings</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="7" style="background-color:#bbbdc0" rowspan="1"><bold>SCHIZOPHRENIA STUDIES</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Schwarz et al., <xref rid="B105" ref-type="bibr">2008</xref></td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">First episode and chronic</td><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="center" rowspan="1" colspan="1">36.85 &#x000b1; 8.4</td><td valign="top" align="left" rowspan="1" colspan="1">Blood (red blood cells)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191;Cer 34:1 and stearic acid under SGA treatment.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smesny et al., <xref rid="B109" ref-type="bibr">2013</xref></td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">First episode</td><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="center" rowspan="1" colspan="1">23.27 &#x000b1; 3.6</td><td valign="top" align="left" rowspan="1" colspan="1">Skin (stratum corneum)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193;Total Cer, &#x02191;Cer AH and NH/AS, &#x02193;Cer EOS and NP.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">He et al., <xref rid="B50" ref-type="bibr">2012</xref></td><td valign="top" align="left" rowspan="1" colspan="1">265</td><td valign="top" align="left" rowspan="1" colspan="1">Chronic</td><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="center" rowspan="1" colspan="1">19&#x02013;67</td><td valign="top" align="left" rowspan="1" colspan="1">Blood (Plasma)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193;PC C38:6.</td></tr><tr><td valign="top" align="left" colspan="7" style="background-color:#bbbdc0" rowspan="1"><bold>METABOLIC SYNDROME STUDIES</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Heilbronn et al., <xref rid="B51" ref-type="bibr">2013</xref></td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">Overfed</td><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="center" rowspan="1" colspan="1">37 &#x000b1; 2</td><td valign="top" align="left" rowspan="1" colspan="1">Blood</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191;Total Cer, C22:0 and C24:0 (correlated with LDL).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lopez et al., <xref rid="B73" ref-type="bibr">2013</xref></td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">DM2</td><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">14.3 &#x000b1; 1.8</td><td valign="top" align="left" rowspan="1" colspan="1">Blood (Plasma)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191;Cer C22:0, C20:0, C18:0, and C24:1 DihydroCer (correlated with adiponectin, HOMA-IR, BMI, fasting glucose, TG).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Majumdar and Mastrandrea, <xref rid="B75" ref-type="bibr">2012</xref></td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">Overweight</td><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="center" rowspan="1" colspan="1">14.6 &#x000b1; 1.2</td><td valign="top" align="left" rowspan="1" colspan="1">Blood (Serum)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191;Cer correlated with TNF-<italic>&#x003b1;</italic>, adiponectin, lipoproteins, and HOMA-IR levels.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ng et al., <xref rid="B86" ref-type="bibr">2015</xref></td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">MS</td><td valign="top" align="left" rowspan="1" colspan="1">Men</td><td valign="top" align="center" rowspan="1" colspan="1">48.6 &#x000b1; 8.5</td><td valign="top" align="left" rowspan="1" colspan="1">Blood (Plasma)</td><td valign="top" align="left" rowspan="1" colspan="1">VLDL apoB-100 directly correlated with longer chain Cer concentrations (C20:0, C22:0, C24:1, C24:0).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Veillon et al., <xref rid="B125" ref-type="bibr">2015</xref></td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">Visceral fat &#x000b1; hyperglycemia/dyslipidemia</td><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="center" rowspan="1" colspan="1">52.1 &#x000b1; 1.5</td><td valign="top" align="left" rowspan="1" colspan="1">Blood (Serum)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191;GM3 species. GM3 d18:1-h24:1 was the best candidate for metabolic screening.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sato et al., <xref rid="B101" ref-type="bibr">2008</xref></td><td valign="top" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">DM2 and hyperlipidemic</td><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="center" rowspan="1" colspan="1">31&#x02013;84</td><td valign="top" align="left" rowspan="1" colspan="1">Blood (Serum)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191;GM3 species. GM3 was directly correlated with LDL.</td></tr></tbody></table><table-wrap-foot><p><italic>&#x02193;, decreased levels; &#x02191;, increased levels; Cer, ceramides; MS, metabolic syndrome; AH, &#x003b1;-hydroxy 6-hydroxysphingosine; NH, nonhydroxy 6-hydroxysphingosine; AS, &#x003b1;-hydroxy sphingosine; EOS, &#x003c9;-hydroxysphingosine; NP, nonhydroxy phytosphingosine; HOMA-IR, Insulin resistance homeostasis model assessment; TNF-&#x003b1;, tumor necrosis factor &#x003b1;; PC, phosphatidylcholine; SGA, second generation antipsychotics; DM, diabetes mellitus; TG, triglycerides; GM3, ganglioside GM3; LDL, low density lipoprotein; VLDL, very low density lipoprotein; BMI, body mass index</italic>.</p></table-wrap-foot></table-wrap><p>There is also evidence showing association between SZ and SLs levels in peripheral samples (Table <xref ref-type="table" rid="T1">1</xref>). Schwarz et al. demonstrated elevations of specific ceramides (C34:1) and FFAs (stearic acid) in peripheral red blood cell samples from SZ patients after using second-generation antipsychotics (Schwarz et al., <xref rid="B105" ref-type="bibr">2008</xref>). The study of Smesny et al. (See Table <xref ref-type="table" rid="T1">1</xref>) supports a SZ-SLs direct association, since they found SLs abnormalities in the stratum corneum of the skin of first-episode drug-na&#x000ef;ve SZ patients, representing a novel and non-invasive test for psychiatric diagnosis (Smesny et al., <xref rid="B109" ref-type="bibr">2013</xref>). The rationale behind this approach is the large representation and structural homology between skin and CNS lipids. In this case, the researchers found only ceramides abnormalities among different classes of skin lipids. Lastly, other studies have found decreased PC, which might be related to increase SMs breakdown and thus increased ceramides levels in SZ patients (Brozinick et al., <xref rid="B15" ref-type="bibr">2013</xref>).</p><p>Whether the association between SLs and SZ is related to only a specific subpopulation of SZ patients at risk to develop MS is still unknown, and future longitudinal studies are necessary in this area. Due to the importance of SLs metabolism in neurodevelopment and in general lipid homeostasis, it is also necessary to explore whether SLs alterations in MS and SZ are indicating a common pathophysiological alteration with different phenotypic manifestations. In this regard, it will be important to recruit SZ patients without central obesity for new studies, so as to demonstrate that metabolic disturbances are independent from classical MS mechanisms in these patients.</p><p>Although the presented studies have diverging purposes, subjects and results, there are relevant common conclusions, which can support the relationships between SZ and SLs metabolism. First, it is possible to measure significant alterations in SLs in peripheral samples like blood and skin cells, which may reflect actual SLs alterations in CNS and other tissues. This is important since it opens the possibility for developing an ideal non-invasive biomarker for a SNC condition. Second, although it is still necessary to have more compelling evidence with proper controls for all MS risk factors, current literature suggest that MS is also present in young antipsychotics-free populations regardless of disease progression and pharmacological treatment. Finally, although the current studies have focused on the analyzes of different subtypes of lipids in biological samples, which make data comparability rather difficult, all of them suggest that the inflammatory/structural ratio of SLs ratio is increased, as a common metabolic feature of SZ and MS. This is interesting if we consider that both, SZ and MS, correspond to complex polygenic alterations and gene-environment interactions. Perhaps a hypo/hyperfunction of some SLs-related enzymes may trigger these abnormalities.</p><p>Consequently, we propose the testable hypothesis that a specific SLs profile from peripheral tissues will serve as a MS biomarker to diagnose and evaluate the natural evolution of MS in psychotic patients. Since SZ is a highly heterogenic disease, this biomarker should allow us to recognize a differential vulnerability for metabolic disturbances among SZ patients. In this context, prodromal and first-episode psychosis populations represent a good and early opportunity to make a complete evaluation in order to target specific preventive interventions for these patients.</p><p>Finally, it is worth mentioning in this review that many of the emerging alternative treatments proposed for SZ [e.g., vitamins (Arroll et al., <xref rid="B6" ref-type="bibr">2014</xref>; Brown and Roffman, <xref rid="B14" ref-type="bibr">2014</xref>), omega-3 fatty acids (Hashimoto et al., <xref rid="B48" ref-type="bibr">2014</xref>), anti-inflammatory agents (Girgis et al., <xref rid="B40" ref-type="bibr">2014</xref>)] can have direct and/or indirect impacts on inflammatory status, membrane lipids profiles, and membrane structural properties (Yaqoob and Shaikh, <xref rid="B133" ref-type="bibr">2010</xref>). Omega-3 fatty acids in particular have important effects on brain functions since docosahexaenoic acid (DHA) is a major structural component of phospholipids in neuronal cell membranes and eicosapentaenoic acid (EPA) shows neurotransmitter and neuromodulatory activity (Fenton et al., <xref rid="B29" ref-type="bibr">2000</xref>) which may have therapeutic properties in psychotic symptoms. In fact, recent evidence has confirmed that young adults with sub-threshold psychotic symptoms lower their risk of developing a psychotic disorder when treated for 12 weeks with a formulation containing omega-3 essential polyunsaturated fatty acids (PUFAs), EPA, DHA, and tocopherol (Vitamin E) (Amminger et al., <xref rid="B4" ref-type="bibr">2010</xref>, <xref rid="B5" ref-type="bibr">2015</xref>). This opens new possibilities to investigate the specific role of SLs metabolism in SZ, with the goal of finding new therapeutic opportunities in SZ.</p></sec></sec><sec sec-type="conclusions" id="s7"><title>Conclusions</title><p>In summary, we have reviewed the evidence linking SLs, MS, and SZ, hinting a plausible common etiopathogenic a mechanism, which explains the clinical features like the vulnerability of these patients to develop metabolic complications, regardless of the presence of antipsychotic drugs, at early stages of the disease. Moreover, dysfunction in SLs pathway may represent an important connecting-piece in understanding the SZ neurobiology, allowing us to link the current diverse theories of SZ pathology (Figure <xref ref-type="fig" rid="F6">6</xref>).</p><fig id="F6" position="float"><label>Figure 6</label><caption><p><bold>Sphingolipids as the central convergence point between metabolic syndrome and schizophrenia</bold>. Environmental factors and intrinsic genetic vulnerability converge in an abnormal sphingolipid metabolism, in this case represented in an increased inflammatory/structural sphingolipid ratio. This alteration might lead to both metabolic and neuronal abnormalities secondarily provoking cardiovascular morbidity and psychotic symptoms.</p></caption><graphic xlink:href="fnins-10-00488-g0006"/></fig><p>As suggested above, measuring specific levels of SLs in biological samples and defining a specific profile of these molecules in skin tests or in peripheral blood samples could help us to anticipate cardiovascular complications and/or to make an early SZ diagnosis, especially in the group of patients at prodromal and first episode of psychosis. By using SLs profiles as MS and/or SZ biomarkers in this population, we could develop a more personalized clinical management to improve the patient's prognosis. Finally, this association opens new possibilities for innovative research in the SLs field toward finding novel pharmacological treatments such as omega-3 fatty acids, which may impact both psychotic and/or metabolic symptoms.</p><p>Future studies should confirm these statements in order to find the most representative profile of SLs involved in SZ and to prove the feasibility and clinical utility of these examinations.</p></sec><sec id="s8"><title>Author contributions</title><p>RC, PG, and LR conceived and outlined the manuscript. RC wrote the manuscript under the supervision of PG and LR. PG contributed with biological and clinical aspects of schizophrenia. LR contributed to describe the links between metabolic syndrome and sphingolipid metabolism (metabolic pathways, signal transductions, etc.). MH contributed with molecular aspects of lipids metabolism in the context of brain physiology. HS edited the entire manuscript and wrote the section on development of future therapeutic technologies. AM contributed to edit the manuscript and wrote the section &#x0201c;Sphingolipids and SZ disconnectivity hypothesis.&#x0201d; MV contributed with the sphingolipds and metabolic syndrome. MF outlined and wrote the relationships between sphingolipids and schizophrenia.</p></sec><sec id="s9"><title>Funding</title><p>RC is supported by CONICYT-PCHA, Doctorado Nacional, 2015-21150063, Ministry of Education, Chile. PG is funded by the National Commission for Scientific and Technological Research (CONICYT), FONDECYT initiation into research 2014, grant No. 11140464 and OAIC grant from the Clinical Hospital of the University of Chile. The Biomedical Neuroscience Institute (BNI) supports PG and HS. LR is funded by the National Commission for Scientific and Technological Research (CONICYT), FONDECYT initiation into research 2014, grant No. 11140915.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer JN and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.</p></sec></sec></body><back><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J. M.</given-names></name><name><surname>Pratipanawatr</surname><given-names>T.</given-names></name><name><surname>Berria</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>E.</given-names></name><name><surname>DeFronzo</surname><given-names>R. A.</given-names></name><name><surname>Sullards</surname><given-names>M. C.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Ceramide content is increased in skeletal muscle from obese insulin-resistant humans</article-title>. <source>Diabetes</source>
<volume>53</volume>, <fpage>25</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.53.1.25</pub-id><?supplied-pmid 14693694?><pub-id pub-id-type="pmid">14693694</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adibhatla</surname><given-names>R. M.</given-names></name><name><surname>Hatcher</surname><given-names>J. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Altered lipid metabolism in brain injury and disorders</article-title>. <source>Subcell. Biochem.</source>
<volume>49</volume>, <fpage>241</fpage>&#x02013;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4020-8831-5_9</pub-id><?supplied-pmid 18751914?><pub-id pub-id-type="pmid">18751914</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>J. A.</given-names></name><name><surname>Halverson-Tamboli</surname><given-names>R. A.</given-names></name><name><surname>Rasenick</surname><given-names>M. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Lipid raft microdomains and neurotransmitter signalling</article-title>. <source>Nat. Rev. Neurosci.</source>
<volume>8</volume>, <fpage>128</fpage>&#x02013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2059</pub-id><?supplied-pmid 17195035?><pub-id pub-id-type="pmid">17195035</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amminger</surname><given-names>G. P.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>M. R.</given-names></name><name><surname>Papageorgiou</surname><given-names>K.</given-names></name><name><surname>Klier</surname><given-names>C. M.</given-names></name><name><surname>Cotton</surname><given-names>S. M.</given-names></name><name><surname>Harrigan</surname><given-names>S. M.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Long-chain &#x003c9;-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>67</volume>, <fpage>146</fpage>&#x02013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.192</pub-id><?supplied-pmid 20124114?><pub-id pub-id-type="pmid">20124114</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amminger</surname><given-names>G. P.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>M. R.</given-names></name><name><surname>Schl&#x000f6;gelhofer</surname><given-names>M.</given-names></name><name><surname>Klier</surname><given-names>C. M.</given-names></name><name><surname>McGorry</surname><given-names>P. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study</article-title>. <source>Nat. Commun.</source>
<volume>6</volume>, <fpage>7934</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8934</pub-id><?supplied-pmid 26263244?><pub-id pub-id-type="pmid">26263244</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arroll</surname><given-names>M. A.</given-names></name><name><surname>Wilder</surname><given-names>L.</given-names></name><name><surname>Neil</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review</article-title>. <source>Nutr. J.</source>
<volume>13</volume>:<fpage>91</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2891-13-91</pub-id><?supplied-pmid 25228271?><pub-id pub-id-type="pmid">25228271</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aureli</surname><given-names>M.</given-names></name><name><surname>Grassi</surname><given-names>S.</given-names></name><name><surname>Prioni</surname><given-names>S.</given-names></name><name><surname>Sonnino</surname><given-names>S.</given-names></name><name><surname>Prinetti</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Lipid membrane domains in the brain</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1851</volume>, <fpage>1006</fpage>&#x02013;<lpage>1016</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2015.02.001</pub-id><?supplied-pmid 25677824?><pub-id pub-id-type="pmid">25677824</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakhshi</surname><given-names>K.</given-names></name><name><surname>Chance</surname><given-names>S. A.</given-names></name></person-group> (<year>2015</year>). <article-title>The neuropathology of schizophrenia: a selective review of past studies and emerging themes in brain structure and cytoarchitecture</article-title>. <source>Neuroscience</source>
<volume>303</volume>, <fpage>82</fpage>&#x02013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.06.028</pub-id><?supplied-pmid 26116523?><pub-id pub-id-type="pmid">26116523</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>H. G.</given-names></name><name><surname>Steiner</surname><given-names>J.</given-names></name><name><surname>Guest</surname><given-names>P. C.</given-names></name><name><surname>Dobrowolny</surname><given-names>H.</given-names></name><name><surname>Bogerts</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy</article-title>. <source>Schizophr. Res.</source>
<volume>161</volume>, <fpage>4</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2014.03.035</pub-id><?supplied-pmid 24948484?><pub-id pub-id-type="pmid">24948484</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>R.</given-names></name><name><surname>Matsushita</surname><given-names>K.</given-names></name><name><surname>Yamakuchi</surname><given-names>M.</given-names></name><name><surname>Morrell</surname><given-names>C. N.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Lowenstein</surname><given-names>C. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Ceramide triggers Weibel-Palade body exocytosis</article-title>. <source>Circ. Res.</source>
<volume>95</volume>, <fpage>319</fpage>&#x02013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1161/01.RES.0000136519.84279.7a</pub-id><?supplied-pmid 15217913?><pub-id pub-id-type="pmid">15217913</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bikman</surname><given-names>B. T.</given-names></name></person-group> (<year>2012</year>). <article-title>A role for sphingolipids in the pathophysiology of obesity-induced inflammation</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>69</volume>, <fpage>2135</fpage>&#x02013;<lpage>2146</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-012-0917-5</pub-id><?supplied-pmid 22294100?><pub-id pub-id-type="pmid">22294100</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>J.</given-names></name><name><surname>Edstr&#x000f6;m</surname><given-names>L.</given-names></name><name><surname>Bjerkenstedt</surname><given-names>L.</given-names></name><name><surname>Wiesel</surname><given-names>F. A.</given-names></name><name><surname>Farde</surname><given-names>L.</given-names></name><name><surname>Hagenfeldt</surname><given-names>L.</given-names></name></person-group> (<year>1987</year>). <article-title>Muscle biopsy findings, conduction velocity and refractory period of single motor nerve fibres in schizophrenia</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>
<volume>50</volume>, <fpage>1655</fpage>&#x02013;<lpage>1664</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.50.12.1655</pub-id><?supplied-pmid 3437297?><pub-id pub-id-type="pmid">3437297</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourbon</surname><given-names>N. A.</given-names></name><name><surname>Sandirasegarane</surname><given-names>L.</given-names></name><name><surname>Kester</surname><given-names>M.</given-names></name></person-group> (<year>2002</year>). <article-title>Ceramide-induced inhibition of Akt is mediated through protein kinase C&#x003b6;: implications for growth arrest</article-title>. <source>J. Biol. Chem.</source>
<volume>277</volume>, <fpage>3286</fpage>&#x02013;<lpage>3292</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110541200</pub-id><?supplied-pmid 11723139?><pub-id pub-id-type="pmid">11723139</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>H. E.</given-names></name><name><surname>Roffman</surname><given-names>J. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Vitamin supplementation in the treatment of schizophrenia</article-title>. <source>CNS Drugs</source>
<volume>28</volume>, <fpage>611</fpage>&#x02013;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1007/s40263-014-0172-4</pub-id><?supplied-pmid 24846474?><pub-id pub-id-type="pmid">24846474</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brozinick</surname><given-names>J. T.</given-names></name><name><surname>Hawkins</surname><given-names>E.</given-names></name><name><surname>Hoang-Bui</surname><given-names>H.</given-names></name><name><surname>Kuo</surname><given-names>M. S.</given-names></name><name><surname>Tan</surname><given-names>B.</given-names></name><name><surname>Kievit</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet</article-title>. <source>Int. J. Obes.</source>
<volume>37</volume>, <fpage>1064</fpage>&#x02013;<lpage>1070</lpage>. <pub-id pub-id-type="doi">10.1038/ijo.2012.191</pub-id><?supplied-pmid 23207405?><pub-id pub-id-type="pmid">23207405</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canu</surname><given-names>E.</given-names></name><name><surname>Agosta</surname><given-names>F.</given-names></name><name><surname>Filippi</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>A selective review of structural connectivity abnormalities of schizophrenic patients at different stages of the disease</article-title>. <source>Schizophr. Res.</source>
<volume>161</volume>, <fpage>19</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2014.05.020</pub-id><?supplied-pmid 24893909?><pub-id pub-id-type="pmid">24893909</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>H.</given-names></name><name><surname>Dixson</surname><given-names>L.</given-names></name><name><surname>Meyer-Lindenberg</surname><given-names>A.</given-names></name><name><surname>Tost</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Functional connectivity measures as schizophrenia intermediate phenotypes: advances, limitations, and future directions</article-title>. <source>Curr. Opin. Neurobiol.</source>
<volume>36</volume>, <fpage>7</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2015.07.008</pub-id><?supplied-pmid 26276700?><pub-id pub-id-type="pmid">26276700</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadda</surname><given-names>R. K.</given-names></name><name><surname>Ramshankar</surname><given-names>P.</given-names></name><name><surname>Deb</surname><given-names>K. S.</given-names></name><name><surname>Sood</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Metabolic syndrome in schizophrenia: differences between antipsychotic-na&#x000ef;ve and treated patients</article-title>. <source>J. Pharmacol. Pharmacother.</source>
<volume>4</volume>, <fpage>176</fpage>&#x02013;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.4103/0976-500X.114596</pub-id><?supplied-pmid 23960422?><pub-id pub-id-type="pmid">23960422</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>G. H.</given-names></name><name><surname>Barbaro</surname><given-names>N. M.</given-names></name><name><surname>Pieper</surname><given-names>R. O.</given-names></name></person-group> (<year>2000</year>). <article-title>Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia, astrocytes, and glioma cells</article-title>. <source>Neuro Oncol.</source>
<volume>2</volume>, <fpage>174</fpage>&#x02013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1215/15228517-2-3-174</pub-id><?supplied-pmid 11302338?><pub-id pub-id-type="pmid">11302338</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavez</surname><given-names>J.</given-names></name><name><surname>Knotts</surname><given-names>T. A.</given-names></name><name><surname>Wang</surname><given-names>L. P.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Dobrowsky</surname><given-names>R. T.</given-names></name><name><surname>Florant</surname><given-names>G. I.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>10297</fpage>&#x02013;<lpage>10303</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M212307200</pub-id><?supplied-pmid 12525490?><pub-id pub-id-type="pmid">12525490</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C.</given-names></name><name><surname>Chiu</surname><given-names>H.-J.</given-names></name><name><surname>Loh</surname><given-names>El-W.</given-names></name><name><surname>Chan</surname><given-names>C.-H.</given-names></name><name><surname>Hwu</surname><given-names>T.-M.</given-names></name><name><surname>Liu</surname><given-names>Y.-R.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia</article-title>. <source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source>
<volume>36</volume>, <fpage>205</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2011.10.011</pub-id><?supplied-pmid 22037178?><pub-id pub-id-type="pmid">22037178</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombaioni</surname><given-names>L.</given-names></name><name><surname>Garcia-Gil</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Sphingolipid metabolites in neural signalling and function</article-title>. <source>Brain Res. Rev.</source>
<volume>46</volume>, <fpage>328</fpage>&#x02013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresrev.2004.07.014</pub-id><?supplied-pmid 15571774?><pub-id pub-id-type="pmid">15571774</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Col&#x000f3;n-S&#x000e1;ez</surname><given-names>J. O.</given-names></name><name><surname>Yakel</surname><given-names>J. L.</given-names></name></person-group> (<year>2011</year>). <article-title>The &#x003b1;7 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane</article-title>. <source>J. Physiol.</source>
<volume>589</volume>, <fpage>3163</fpage>&#x02013;<lpage>3174</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2011.209494</pub-id><?supplied-pmid 21540349?><pub-id pub-id-type="pmid">21540349</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowart</surname><given-names>L. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Sphingolipids: players in the pathology of metabolic disease</article-title>. <source>Trends. Endocrinol. Metab</source>
<volume>20</volume>, <fpage>34</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2008.09.004</pub-id><?supplied-pmid 19008117?><pub-id pub-id-type="pmid">19008117</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>K. L.</given-names></name><name><surname>Stewart</surname><given-names>D. G.</given-names></name><name><surname>Friedman</surname><given-names>J. I.</given-names></name><name><surname>Buchsbaum</surname><given-names>M.</given-names></name><name><surname>Harvey</surname><given-names>P. D.</given-names></name><name><surname>Hof</surname><given-names>P. R.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>White matter changes in schizophrenia: evidence for myelin-related dysfunction</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>60</volume>, <fpage>443</fpage>&#x02013;<lpage>456</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.60.5.443</pub-id><?supplied-pmid 12742865?><pub-id pub-id-type="pmid">12742865</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De-Hert</surname><given-names>M.</given-names></name><name><surname>Dekker</surname><given-names>J. M.</given-names></name><name><surname>Wood</surname><given-names>D.</given-names></name><name><surname>Kahl</surname><given-names>K. G.</given-names></name><name><surname>Holt</surname><given-names>R. I.</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>H. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and European Society of Cardiology (ESC)</article-title>. <source>Eur. Psychiatry</source>
<volume>24</volume>, <fpage>412</fpage>&#x02013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1016/j.eurpsy.2009.01.005</pub-id><?supplied-pmid 19682863?><pub-id pub-id-type="pmid">19682863</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebel</surname><given-names>P.</given-names></name><name><surname>Vom Dorp</surname><given-names>K.</given-names></name><name><surname>Petrasch-Parwez</surname><given-names>E.</given-names></name><name><surname>Zlomuzica</surname><given-names>A.</given-names></name><name><surname>Kinugawa</surname><given-names>K.</given-names></name><name><surname>Mariani</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Inactivation of ceramide synthase 6 in mice results in an altered sphingolipid metabolism and behavioral abnormalities</article-title>. <source>J. Biol. Chem.</source>
<volume>288</volume>, <fpage>21433</fpage>&#x02013;<lpage>21447</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.479907</pub-id><?supplied-pmid 23760501?><pub-id pub-id-type="pmid">23760501</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellingrod</surname><given-names>V. L.</given-names></name><name><surname>Miller</surname><given-names>D. D.</given-names></name><name><surname>Taylor</surname><given-names>S. F.</given-names></name><name><surname>Moline</surname><given-names>J.</given-names></name><name><surname>Holman</surname><given-names>T.</given-names></name><name><surname>Kerr</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants</article-title>. <source>Schizophr. Res.</source>
<volume>98</volume>, <fpage>47</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2007.09.030</pub-id><?supplied-pmid 17976958?><pub-id pub-id-type="pmid">17976958</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenton</surname><given-names>W. S.</given-names></name><name><surname>Hibbeln</surname><given-names>J.</given-names></name><name><surname>Knable</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia</article-title>. <source>Biol. Psychiatry</source>
<volume>47</volume>, <fpage>8</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-3223(99)00092-X</pub-id><?supplied-pmid 10650444?><pub-id pub-id-type="pmid">10650444</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Egea</surname><given-names>E.</given-names></name><name><surname>Bernardo</surname><given-names>M.</given-names></name><name><surname>Donner</surname><given-names>D.</given-names></name><name><surname>Conget</surname><given-names>I.</given-names></name><name><surname>Parellada</surname><given-names>E.</given-names></name><name><surname>Justicia</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Metabolic profile of antipsychotic-na&#x000ef;ve individuals with non-affective psychosis</article-title>. <source>Br. J. Psychiatry</source>
<volume>194</volume>, <fpage>434</fpage>&#x02013;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.bp.108.052605</pub-id><?supplied-pmid 19407273?><pub-id pub-id-type="pmid">19407273</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Egea</surname><given-names>E.</given-names></name><name><surname>Bernardo</surname><given-names>M.</given-names></name><name><surname>Parellada</surname><given-names>E.</given-names></name><name><surname>Justicia</surname><given-names>A.</given-names></name><name><surname>Garcia-Rizo</surname><given-names>C.</given-names></name><name><surname>Esmatjes</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2008a</year>). <article-title>Glucose abnormalities in the siblings of people with schizophrenia</article-title>. <source>Schizophr. Res.</source>
<volume>103</volume>, <fpage>110</fpage>&#x02013;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2008.04.017</pub-id><?supplied-pmid 18514487?><pub-id pub-id-type="pmid">18514487</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Egea</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>B.</given-names></name><name><surname>Bernardo</surname><given-names>M.</given-names></name><name><surname>Donner</surname><given-names>T.</given-names></name><name><surname>Kirkpatrick</surname><given-names>B.</given-names></name></person-group> (<year>2008b</year>). <article-title>Parental history of type 2 diabetes in patients with nonaffective psychosis</article-title>. <source>Schizophr. Res.</source>
<volume>98</volume>, <fpage>302</fpage>&#x02013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2007.10.002</pub-id><?supplied-pmid 18031995?><pub-id pub-id-type="pmid">18031995</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filakovi&#x00107;</surname><given-names>P.</given-names></name><name><surname>Petek Eri&#x00107;</surname><given-names>A.</given-names></name><name><surname>Radanovi&#x00107;-Grguri&#x00107;</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>Metabolic syndrome and psychotropic medications</article-title>. <source>Med. Glas. (Zenica)</source>
<volume>9</volume>, <fpage>180</fpage>&#x02013;<lpage>188</lpage>. <?supplied-pmid 22926348?><pub-id pub-id-type="pmid">22926348</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flyckt</surname><given-names>L.</given-names></name><name><surname>Borg</surname><given-names>J.</given-names></name><name><surname>Borg</surname><given-names>K.</given-names></name><name><surname>Ansved</surname><given-names>T.</given-names></name><name><surname>Edman</surname><given-names>G.</given-names></name><name><surname>Bjerkenstedt</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>Muscle biopsy, macro EMG, and clinical characteristics in patients with schizophrenia</article-title>. <source>Biol. Psychiatry</source>
<volume>47</volume>, <fpage>991</fpage>&#x02013;<lpage>999</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-3223(99)00295-4</pub-id><?supplied-pmid 10838067?><pub-id pub-id-type="pmid">10838067</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>J. M.</given-names></name><name><surname>Krystal</surname><given-names>J. H.</given-names></name><name><surname>Mathalon</surname><given-names>D. H.</given-names></name></person-group> (<year>2007</year>). <article-title>Neural synchrony in schizophrenia: from networks to new treatments</article-title>. <source>Schizophr. Bull.</source>
<volume>33</volume>, <fpage>848</fpage>&#x02013;<lpage>852</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbm062</pub-id><?supplied-pmid 17567628?><pub-id pub-id-type="pmid">17567628</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garver</surname><given-names>D. L.</given-names></name><name><surname>Holcomb</surname><given-names>J. A.</given-names></name><name><surname>Christensen</surname><given-names>J. D.</given-names></name></person-group> (<year>2008</year>). <article-title>Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia</article-title>. <source>Int. J. Neuropsychopharmacol.</source>
<volume>11</volume>, <fpage>49</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145707007730</pub-id><?supplied-pmid 17708778?><pub-id pub-id-type="pmid">17708778</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>P. A.</given-names></name><name><surname>Bustamante</surname><given-names>M. L.</given-names></name><name><surname>Rojo</surname><given-names>L. E.</given-names></name><name><surname>Martinez</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>From glutamatergic dysfunction to cognitive impairment: boundaries in the therapeutic of the schizophrenia</article-title>. <source>Curr. Pharm. Biotechnol.</source>
<volume>13</volume>, <fpage>1543</fpage>&#x02013;<lpage>1548</lpage>. <pub-id pub-id-type="doi">10.2174/138920112800784790</pub-id><?supplied-pmid 22283759?><pub-id pub-id-type="pmid">22283759</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>P. A.</given-names></name><name><surname>Bustamante</surname><given-names>M. L.</given-names></name><name><surname>Silva</surname><given-names>H.</given-names></name><name><surname>Aboitiz</surname><given-names>F.</given-names></name></person-group> (<year>2009</year>). <article-title>Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications</article-title>. <source>J. Neurochem.</source>
<volume>111</volume>, <fpage>891</fpage>&#x02013;<lpage>900</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06325.x</pub-id><?supplied-pmid 19686383?><pub-id pub-id-type="pmid">19686383</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginkel</surname><given-names>C.</given-names></name><name><surname>Hartmann</surname><given-names>D.</given-names></name><name><surname>Vom Dorp</surname><given-names>K.</given-names></name><name><surname>Zlomuzica</surname><given-names>A.</given-names></name><name><surname>Farwanah</surname><given-names>H.</given-names></name><name><surname>Eckhardt</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Ablation of neuronal ceramide synthase 1 in mice decreases ganglioside levels and expression of myelin-associated glycoprotein in oligodendrocytes</article-title>. <source>J. Biol. Chem.</source>
<volume>287</volume>, <fpage>41888</fpage>&#x02013;<lpage>41902</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.413500</pub-id><?supplied-pmid 23074226?><pub-id pub-id-type="pmid">23074226</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girgis</surname><given-names>R. R.</given-names></name><name><surname>Kumar</surname><given-names>S. S.</given-names></name><name><surname>Brown</surname><given-names>A. S.</given-names></name></person-group> (<year>2014</year>). <article-title>The cytokine model of schizophrenia: emerging therapeutic strategies</article-title>. <source>Biol. Psychiatry</source>
<volume>75</volume>, <fpage>292</fpage>&#x02013;<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2013.12.002</pub-id><?supplied-pmid 24439555?><pub-id pub-id-type="pmid">24439555</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Q.</given-names></name><name><surname>Lui</surname><given-names>S.</given-names></name><name><surname>Sweeney</surname><given-names>J. A.</given-names></name></person-group> (<year>2016</year>). <article-title>A selective review of cerebral abnormalities in patients with first-episode schizophrenia before and after treatment</article-title>. <source>Am. J. Psychiatry</source>
<volume>173</volume>, <fpage>232</fpage>&#x02013;<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2015.15050641</pub-id><?supplied-pmid 26621570?><pub-id pub-id-type="pmid">26621570</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Burgos</surname><given-names>G.</given-names></name><name><surname>Lewis</surname><given-names>D. A.</given-names></name></person-group> (<year>2012</year>). <article-title>NMDA receptor hypofunction, parvalbumin-positive neurons and cortical gamma oscillations in Schizophrenia</article-title>. <source>Schizophr. Bull.</source>
<volume>38</volume>, <fpage>950</fpage>&#x02013;<lpage>957</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbs010</pub-id><?supplied-pmid 22355184?><pub-id pub-id-type="pmid">22355184</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goudriaan</surname><given-names>A.</given-names></name><name><surname>de Leeuw</surname><given-names>C.</given-names></name><name><surname>Ripke</surname><given-names>S.</given-names></name><name><surname>Hultman</surname><given-names>C. M.</given-names></name><name><surname>Sklar</surname><given-names>P.</given-names></name><name><surname>Sullivan</surname><given-names>P. F.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Specific glial functions contribute to schizophrenia susceptibility</article-title>. <source>Schizophr. Bull.</source>
<volume>40</volume>, <fpage>925</fpage>&#x02013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbt109</pub-id><?supplied-pmid 23956119?><pub-id pub-id-type="pmid">23956119</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guest</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Harris</surname><given-names>L.</given-names></name><name><surname>Burling</surname><given-names>K.</given-names></name><name><surname>Levin</surname><given-names>Y.</given-names></name><name><surname>Ernst</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Increased levels of circulating insulin-related peptides in first onset, antipsychotic na&#x000ef;ve schizophrenia patients</article-title>. <source>Mol. Psychiatry</source>
<volume>15</volume>, <fpage>118</fpage>&#x02013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2009.81</pub-id><?supplied-pmid 20098438?><pub-id pub-id-type="pmid">20098438</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyton</surname><given-names>J. R.</given-names></name><name><surname>Klemp</surname><given-names>K. F.</given-names></name></person-group> (<year>1996</year>). <article-title>Development of the lipid-rich core in human atherosclerosis</article-title>. <source>Arterioescler. Thromb. Vasc. Biol.</source>
<volume>16</volume>, <fpage>4</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1161/01.ATV.16.1.4</pub-id><?supplied-pmid 8548424?><pub-id pub-id-type="pmid">8548424</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakak</surname><given-names>Y.</given-names></name><name><surname>Walker</surname><given-names>J. R.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>W. H.</given-names></name><name><surname>Davis</surname><given-names>K. L.</given-names></name><name><surname>Buxbaum</surname><given-names>J. D.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>98</volume>, <fpage>4746</fpage>&#x02013;<lpage>4751</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.081071198</pub-id><?supplied-pmid 11296301?><pub-id pub-id-type="pmid">11296301</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannun</surname><given-names>Y. A.</given-names></name><name><surname>Obeid</surname><given-names>L. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Principles of bioactive lipid signaling: lessons from sphingolipids</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>9</volume>, <fpage>139</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2329</pub-id><?supplied-pmid 18216770?><pub-id pub-id-type="pmid">18216770</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Maekawa</surname><given-names>M.</given-names></name><name><surname>Katakura</surname><given-names>M.</given-names></name><name><surname>Hamazaki</surname><given-names>K.</given-names></name><name><surname>Matsuoka</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Possibility of polyunsaturated fatty acids for the prevention and treatment of neuropsychiatric illnesses</article-title>. <source>J. Pharmacol. Sci.</source>
<volume>124</volume>, <fpage>294</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1254/jphs.13R14CP</pub-id><?supplied-pmid 24561447?><pub-id pub-id-type="pmid">24561447</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haughey</surname><given-names>N. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Sphingolipids in neurodegeneration</article-title>. <source>Neuromolecular Med.</source>
<volume>12</volume>, <fpage>301</fpage>&#x02013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1007/s12017-010-8135-5</pub-id><?supplied-pmid 20737248?><pub-id pub-id-type="pmid">20737248</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Giegling</surname><given-names>I.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Hartmann</surname><given-names>A. M.</given-names></name><name><surname>Prehn</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Schizophrenia shows a unique metabolomics signature in plasma</article-title>. <source>Transl. Psychiatry</source>
<volume>2</volume>:<fpage>e149</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2012.76</pub-id><?supplied-pmid 22892715?><pub-id pub-id-type="pmid">22892715</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilbronn</surname><given-names>L. K.</given-names></name><name><surname>Coster</surname><given-names>A. C. F.</given-names></name><name><surname>Campbell</surname><given-names>L. V.</given-names></name><name><surname>Greenfield</surname><given-names>J. R.</given-names></name><name><surname>Lange</surname><given-names>K.</given-names></name><name><surname>Christopher</surname><given-names>M. J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>The effect of short term overfeeding on serum lipids in healthy humans</article-title>. <source>Obesity</source>
<volume>21</volume>, <fpage>E649</fpage>&#x02013;<lpage>E659</lpage>. <pub-id pub-id-type="doi">10.1002/oby.20508</pub-id><?supplied-pmid 23640727?><pub-id pub-id-type="pmid">23640727</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hla</surname><given-names>T.</given-names></name><name><surname>Kolesnick</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>C16:0-ceramide signals insulin resistance</article-title>. <source>Cell Metab.</source>
<volume>20</volume>, <fpage>703</fpage>&#x02013;<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2014.10.017</pub-id><?supplied-pmid 25440051?><pub-id pub-id-type="pmid">25440051</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>W. L.</given-names></name><name><surname>Knotts</surname><given-names>T. A.</given-names></name><name><surname>Chavez</surname><given-names>J. A.</given-names></name><name><surname>Wang</surname><given-names>L. P.</given-names></name><name><surname>Hoehn</surname><given-names>K. L.</given-names></name><name><surname>Summers</surname><given-names>S. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Lipid mediatiors of insulin resistance</article-title>. <source>Nutr. Rev.</source>
<volume>65</volume>, <fpage>S39</fpage>&#x02013;<lpage>S46</lpage>. <pub-id pub-id-type="doi">10.1301/nr.2007.jun.S39-S46</pub-id><?supplied-pmid 17605313?><pub-id pub-id-type="pmid">17605313</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>W. L.</given-names></name><name><surname>Summers</surname><given-names>S. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Sphingolipids, insulin resistance and metabolic disease: new insights from <italic>in vivo</italic> manipulation of sphingolipid metabolism</article-title>. <source>Endocr. Rev.</source>
<volume>29</volume>, <fpage>381</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1210/er.2007-0025</pub-id><?supplied-pmid 18451260?><pub-id pub-id-type="pmid">18451260</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horrobin</surname><given-names>D. F.</given-names></name></person-group> (<year>1998</year>). <article-title>The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia</article-title>. <source>Schizophr. Res.</source>
<volume>30</volume>, <fpage>193</fpage>&#x02013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1016/S0920-9964(97)00151-5</pub-id><?supplied-pmid 9589514?><pub-id pub-id-type="pmid">9589514</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imgrund</surname><given-names>S.</given-names></name><name><surname>Hartmann</surname><given-names>D.</given-names></name><name><surname>Farwanah</surname><given-names>H.</given-names></name><name><surname>Eckhardt</surname><given-names>M.</given-names></name><name><surname>Sandhoff</surname><given-names>R.</given-names></name><name><surname>Degen</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Adult Ceramide Synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas</article-title>. <source>J. Biol. Chem.</source>
<volume>284</volume>, <fpage>33549</fpage>&#x02013;<lpage>33560</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.031971</pub-id><?supplied-pmid 19801672?><pub-id pub-id-type="pmid">19801672</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isomaa</surname><given-names>B.</given-names></name><name><surname>Almgern</surname><given-names>P.</given-names></name><name><surname>Tuomi</surname><given-names>T.</given-names></name><name><surname>Fors&#x000e9;n</surname><given-names>B.</given-names></name><name><surname>Lahti</surname><given-names>K.</given-names></name><name><surname>Niss&#x000e9;n</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Cardiovascular morbidity and mortality associated with the metabolic syndrome</article-title>. <source>Diabetes Care</source>
<volume>24</volume>, <fpage>683</fpage>&#x02013;<lpage>689</lpage>. <pub-id pub-id-type="doi">10.2337/diacare.24.4.683</pub-id><?supplied-pmid 11315831?><pub-id pub-id-type="pmid">11315831</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>S.</given-names></name><name><surname>Iwaki</surname><given-names>S.</given-names></name><name><surname>Koike</surname><given-names>K.</given-names></name><name><surname>Yuda</surname><given-names>Y.</given-names></name><name><surname>Nagasaki</surname><given-names>A.</given-names></name><name><surname>Ohkawa</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Increased plasma sphingosine-1-phosphate in obese individuals and its capacity to increase the expression of plasminogen activator inhibitor-1 in adipocytes</article-title>. <source>Coron. Artery Dis.</source>
<volume>24</volume>, <fpage>642</fpage>&#x02013;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1097/mca.0000000000000033</pub-id><?supplied-pmid 24212262?><pub-id pub-id-type="pmid">24212262</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackman</surname><given-names>N.</given-names></name><name><surname>Ishii</surname><given-names>A.</given-names></name><name><surname>Bansal</surname><given-names>R.</given-names></name></person-group> (<year>2009</year>). <article-title>Oligodendrocyte development and myelin biogenesis: parsing out the roles of glycosphingolipids</article-title>. <source>Physiology</source>
<volume>24</volume>, <fpage>290</fpage>&#x02013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1152/physiol.00016.2009</pub-id><?supplied-pmid 19815855?><pub-id pub-id-type="pmid">19815855</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jana</surname><given-names>A.</given-names></name><name><surname>Hogan</surname><given-names>E. L.</given-names></name><name><surname>Pahan</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death</article-title>. <source>J. Neurol. Sci.</source>
<volume>278</volume>, <fpage>5</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2008.12.010</pub-id><?supplied-pmid 19147160?><pub-id pub-id-type="pmid">19147160</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarskog</surname><given-names>L. F.</given-names></name><name><surname>Glantz</surname><given-names>L. A.</given-names></name><name><surname>Gilmore</surname><given-names>J. H.</given-names></name><name><surname>Lieberman</surname><given-names>J. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Apoptotic mechanisms in the pathophysiology of schizophrenia</article-title>. <source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source>
<volume>29</volume>, <fpage>846</fpage>&#x02013;<lpage>858</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.03.010</pub-id><?supplied-pmid 15908096?><pub-id pub-id-type="pmid">15908096</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennemann</surname><given-names>R.</given-names></name><name><surname>Sandhoff</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Kiss</surname><given-names>E.</given-names></name><name><surname>Gretz</surname><given-names>N.</given-names></name><name><surname>Zuliani</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>102</volume>, <fpage>12459</fpage>&#x02013;<lpage>12464</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0500893102</pub-id><?supplied-pmid 16109770?><pub-id pub-id-type="pmid">16109770</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Meyer</surname><given-names>J. M.</given-names></name><name><surname>Jeste</surname><given-names>D. V.</given-names></name></person-group> (<year>2004</year>). <article-title>Atypical antipsychotics and glucose dysregulation: a systematic review</article-title>. <source>Schizophr. Res.</source>
<volume>71</volume>, <fpage>195</fpage>&#x02013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2004.03.024</pub-id><?supplied-pmid 15474892?><pub-id pub-id-type="pmid">15474892</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabayama</surname><given-names>K.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Kitamura</surname><given-names>F.</given-names></name><name><surname>Uemura</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>B. W.</given-names></name><name><surname>Igarashi</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>TNF&#x003b1;-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3</article-title>. <source>Glycobiology</source>
<volume>15</volume>, <fpage>21</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1093/glycob/cwh135</pub-id><?supplied-pmid 15306563?><pub-id pub-id-type="pmid">15306563</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>R. S.</given-names></name><name><surname>Sommer</surname><given-names>I. E.</given-names></name></person-group> (<year>2015</year>). <article-title>The neurobiology and treatment of first-episode schizophrenia</article-title>. <source>Mol. Psychiatry</source>
<volume>20</volume>, <fpage>84</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2014.66</pub-id><?supplied-pmid 25048005?><pub-id pub-id-type="pmid">25048005</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>W. E.</given-names></name><name><surname>Piehler</surname><given-names>A.</given-names></name><name><surname>Wenzel</surname><given-names>J. J.</given-names></name></person-group> (<year>2006</year>). <article-title>ABC A-subfamily transporters: structure, function and disease</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1762</volume>, <fpage>510</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2006.01.011</pub-id><?supplied-pmid 16540294?><pub-id pub-id-type="pmid">16540294</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>A comprehensive review on metabolic syndrome</article-title>. <source>Cardiol. Res. Pract.</source>
<volume>2014</volume>:<fpage>943162</fpage>. <pub-id pub-id-type="doi">10.1155/2014/943162</pub-id><?supplied-pmid 24711954?><pub-id pub-id-type="pmid">24711954</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>A.</given-names></name><name><surname>Takanezawa</surname><given-names>Y.</given-names></name><name><surname>Hirata</surname><given-names>T.</given-names></name><name><surname>Shimizu</surname><given-names>Y.</given-names></name><name><surname>Misasa</surname><given-names>K.</given-names></name><name><surname>Kioka</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1</article-title>. <source>J. Lipid Res.</source>
<volume>47</volume>, <fpage>1791</fpage>&#x02013;<lpage>1802</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M500546-JLR200</pub-id><?supplied-pmid 16702602?><pub-id pub-id-type="pmid">16702602</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolter</surname><given-names>T.</given-names></name><name><surname>Sandhoff</surname><given-names>K.</given-names></name></person-group> (<year>2006</year>). <article-title>Sphingolipid metabolism diseases</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1758</volume>, <fpage>2057</fpage>&#x02013;<lpage>2079</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2006.05.027</pub-id><?supplied-pmid 16854371?><pub-id pub-id-type="pmid">16854371</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornhuber</surname><given-names>J.</given-names></name><name><surname>Reichel</surname><given-names>M.</given-names></name><name><surname>Tripal</surname><given-names>P.</given-names></name><name><surname>Groemer</surname><given-names>T. W.</given-names></name><name><surname>Henkel</surname><given-names>A. W.</given-names></name><name><surname>M&#x000fc;hle</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>The role of ceramide in major depressive disorder</article-title>. <source>Eur. Arch. Psychiatry Clin. Neurosci.</source>
<volume>259</volume>, <fpage>S199</fpage>&#x02013;<lpage>S204</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-009-0061-x</pub-id><?supplied-pmid 19876679?><pub-id pub-id-type="pmid">19876679</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyriakopoulos</surname><given-names>M.</given-names></name><name><surname>Bargiotas</surname><given-names>T.</given-names></name><name><surname>Barker</surname><given-names>G. J.</given-names></name><name><surname>Frangou</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Diffusion tensor imaging in schizophrenia</article-title>. <source>Eur. Psychiatry</source>
<volume>23</volume>, <fpage>255</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1016/j.eurpsy.2007.12.004</pub-id><?supplied-pmid 22841128?><pub-id pub-id-type="pmid">18524546</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahari</surname><given-names>S.</given-names></name><name><surname>Futerman</surname><given-names>A. H.</given-names></name></person-group> (<year>2007</year>). <article-title>The metabolism and function of sphingolipids and glycosphingolipids</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>64</volume>, <fpage>2270</fpage>&#x02013;<lpage>2284</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-007-7076-0</pub-id><?supplied-pmid 17558466?><pub-id pub-id-type="pmid">17558466</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>X.</given-names></name><name><surname>Goldfine</surname><given-names>A. B.</given-names></name><name><surname>Holland</surname><given-names>W. L.</given-names></name><name><surname>Gordillo</surname><given-names>R.</given-names></name><name><surname>Scherer</surname><given-names>P. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. <italic>J. Pediatr. Endocrinol</italic></article-title>. <source>Metab.</source>
<volume>26</volume>, <fpage>995</fpage>&#x02013;<lpage>998</lpage>. <pub-id pub-id-type="doi">10.1515/jpem-2012-0407</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maceyka</surname><given-names>M.</given-names></name><name><surname>Spiegel</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Sphingolipid metabolites in inflammatory disease</article-title>. <source>Nature</source>
<volume>510</volume>, <fpage>58</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1038/nature13475</pub-id><?supplied-pmid 24899305?><pub-id pub-id-type="pmid">24899305</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumdar</surname><given-names>I.</given-names></name><name><surname>Mastrandrea</surname><given-names>L. D.</given-names></name></person-group> (<year>2012</year>). <article-title>Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome</article-title>. <source>Endocrine</source>
<volume>41</volume>, <fpage>442</fpage>&#x02013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1007/s12020-011-9589-4</pub-id><?supplied-pmid 22228496?><pub-id pub-id-type="pmid">22228496</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>N.</given-names></name><name><surname>Grover</surname><given-names>S.</given-names></name><name><surname>Chakrabarti</surname><given-names>S.</given-names></name><name><surname>Kulhara</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Metabolic syndrome in schizophrenia</article-title>. <source>Indian J. Psychol. Med.</source>
<volume>35</volume>, <fpage>227</fpage>&#x02013;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.4103/0253-7176.119471</pub-id><?supplied-pmid 24249923?><pub-id pub-id-type="pmid">24249923</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallat</surname><given-names>Z.</given-names></name><name><surname>Tedgui</surname><given-names>A.</given-names></name></person-group> (<year>2001</year>). <article-title>Current perpective on the role of apoptosis in atherothrombotic disease</article-title>. <source>Circ. Res.</source>
<volume>88</volume>, <fpage>998</fpage>&#x02013;<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1161/hh1001.090571</pub-id><?supplied-pmid 11375268?><pub-id pub-id-type="pmid">11375268</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>Y.</given-names></name><name><surname>Funahanashi</surname><given-names>T.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism</article-title>. <source>J. Atheroscler. Thromb.</source>
<volume>18</volume>, <fpage>629</fpage>&#x02013;<lpage>639</lpage>. <pub-id pub-id-type="doi">10.5551/jat.7922</pub-id><?supplied-pmid 21737960?><pub-id pub-id-type="pmid">21737960</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>A. H.</given-names></name><name><surname>Wang</surname><given-names>E.</given-names></name><name><surname>Mullins</surname><given-names>R. E.</given-names></name></person-group> (<year>1988</year>). <article-title>Kinetics of long-chain (sphingoid) base biosynthesis in intact LM cells: effects of varying the extracellular concentrations of serine and fatty acid precursors of this pathway</article-title>. <source>Biochemistry</source>
<volume>27</volume>, <fpage>340</fpage>&#x02013;<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1021/bi00401a051</pub-id><?supplied-pmid 3126810?><pub-id pub-id-type="pmid">3126810</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mielke</surname><given-names>M. M.</given-names></name><name><surname>Haughey</surname><given-names>N. J.</given-names></name><name><surname>Ratnam-Bandaru</surname><given-names>V. V.</given-names></name><name><surname>Schech</surname><given-names>S.</given-names></name><name><surname>Carrick</surname><given-names>R.</given-names></name><name><surname>Carlson</surname><given-names>M. C.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss</article-title>. <source>Alzheimers Dement.</source>
<volume>6</volume>, <fpage>378</fpage>&#x02013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2010.03.014</pub-id><?supplied-pmid 20813340?><pub-id pub-id-type="pmid">20813340</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;hle</surname><given-names>C.</given-names></name><name><surname>Reichel</surname><given-names>M.</given-names></name><name><surname>Gulbins</surname><given-names>E.</given-names></name><name><surname>Kornhuber</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Sphingolipids in psychiatric disorders and pain syndromes</article-title>. <source>Handb. Exp. Pharmacol.</source>
<volume>216</volume>, <fpage>431</fpage>&#x02013;<lpage>456</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-7091-1511-4_22</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>N.</given-names></name><name><surname>Weidinger</surname><given-names>E.</given-names></name><name><surname>Leitner</surname><given-names>B.</given-names></name><name><surname>Schwarz</surname><given-names>M. J.</given-names></name></person-group> (<year>2015</year>). <article-title>The role of inflammation in schizophrenia</article-title>. <source>Front. Neurosci.</source>
<volume>9</volume>:<fpage>372</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2015.00372</pub-id><?supplied-pmid 26539073?><pub-id pub-id-type="pmid">26539073</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najjar</surname><given-names>S.</given-names></name><name><surname>Pearlman</surname><given-names>D. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Neuroinflammation and white matter pathology in schizophrenia: systematic review</article-title>. <source>Schizophr. Res.</source>
<volume>161</volume>, <fpage>102</fpage>&#x02013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2014.04.041</pub-id><?supplied-pmid 24948485?><pub-id pub-id-type="pmid">24948485</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayan</surname><given-names>S.</given-names></name><name><surname>Head</surname><given-names>S. R.</given-names></name><name><surname>Gilmartin</surname><given-names>T. J.</given-names></name><name><surname>Dean</surname><given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Evidence for disruption of sphingolipid metabolism in schizophrenia</article-title>. <source>J. Neurosci. Res.</source>
<volume>87</volume>, <fpage>278</fpage>&#x02013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.21822</pub-id><?supplied-pmid 18683247?><pub-id pub-id-type="pmid">18683247</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayan</surname><given-names>S.</given-names></name><name><surname>Thomas</surname><given-names>E. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Sphingolipid abnormalities in psychiatric disorders: a missing link in pathology?</article-title>
<source>Front. Biosci. (Landmark Ed)</source>
<volume>16</volume>, <fpage>1797</fpage>&#x02013;<lpage>1810</lpage>. <pub-id pub-id-type="doi">10.2741/3822</pub-id><?supplied-pmid 21196265?><pub-id pub-id-type="pmid">21196265</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>T. W.</given-names></name><name><surname>Ooi</surname><given-names>E. M.</given-names></name><name><surname>Watts</surname><given-names>G. F.</given-names></name><name><surname>Chan</surname><given-names>D. C.</given-names></name><name><surname>Meikle</surname><given-names>P. J.</given-names></name><name><surname>Barrett</surname><given-names>P. H.</given-names></name></person-group> (<year>2015</year>). <article-title>Association of plasma ceramides and sphingomyelin with VLDL apoB-100 fractional catabolic rate before and after rosuvastatin treatment</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>100</volume>, <fpage>2497</fpage>&#x02013;<lpage>2501</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2014-4348</pub-id><?supplied-pmid 25816050?><pub-id pub-id-type="pmid">25816050</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>Y.-F.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Bao</surname><given-names>X.-F.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>GM1 ganglioside reverses the cognitive deficits induced by MK801 in mice</article-title>. <source>Behav. Pharmacol.</source>
<volume>27</volume>, <fpage>451</fpage>&#x02013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1097/fbp.0000000000000229</pub-id><?supplied-pmid 26960162?><pub-id pub-id-type="pmid">26960162</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oresic</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Obesity and psychotic disorders: uncovering common mechanisms through metabolomics</article-title>. <source>Dis. Model. Mech.</source>
<volume>5</volume>, <fpage>614</fpage>&#x02013;<lpage>620</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.009845</pub-id><?supplied-pmid 22915023?><pub-id pub-id-type="pmid">22915023</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papanastasiou</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review</article-title>. <source>Ther. Adv. Psychopharmacol.</source>
<volume>3</volume>, <fpage>33</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1177/2045125312464385</pub-id><?supplied-pmid 23983991?><pub-id pub-id-type="pmid">23983991</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J. W.</given-names></name><name><surname>Park</surname><given-names>W. J.</given-names></name><name><surname>Futerman</surname><given-names>A. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Ceramide synthases as potential targets for therapeutic intervention in human diseases</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1841</volume>, <fpage>671</fpage>&#x02013;<lpage>681</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2013.08.019</pub-id><?supplied-pmid 24021978?><pub-id pub-id-type="pmid">24021978</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>W. J.</given-names></name><name><surname>Park</surname><given-names>J. W.</given-names></name></person-group> (<year>2015</year>). <article-title>The effect of altered sphingolipid acyl chain length on various disease models</article-title>. <source>Biol. Chem.</source>
<volume>396</volume>, <fpage>693</fpage>&#x02013;<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2014-0310</pub-id><?supplied-pmid 25720066?><pub-id pub-id-type="pmid">25720066</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peet</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Diet, diabetes and schizophrenia: review and hypothesis</article-title>. <source>Br. J. Psychiatry Suppl.</source>
<volume>47</volume>, <fpage>S102</fpage>&#x02013;<lpage>S105</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.184.47.s102</pub-id><?supplied-pmid 15056602?><pub-id pub-id-type="pmid">15056602</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccinini</surname><given-names>M.</given-names></name><name><surname>Scandroglio</surname><given-names>F.</given-names></name><name><surname>Prioni</surname><given-names>S.</given-names></name><name><surname>Buccinn&#x000e0;</surname><given-names>B.</given-names></name><name><surname>Loberto</surname><given-names>N.</given-names></name><name><surname>Aureli</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders</article-title>. <source>Mol. Neurobiol.</source>
<volume>41</volume>, <fpage>314</fpage>&#x02013;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-009-8096-6</pub-id><?supplied-pmid 20127207?><pub-id pub-id-type="pmid">20127207</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posse de Chaves</surname><given-names>E. I.</given-names></name></person-group> (<year>2006</year>). <article-title>Sphingolipids in apoptosis, survival and regeneration in the nervous system</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1758</volume>, <fpage>1995</fpage>&#x02013;<lpage>2015</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2006.09.018</pub-id><?supplied-pmid 17084809?><pub-id pub-id-type="pmid">17084809</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raichur</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>S. T.</given-names></name><name><surname>Chan</surname><given-names>P. W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ching</surname><given-names>J.</given-names></name><name><surname>Chaurasia</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>CerS2 haploinsufficiency inhibits &#x003b2;-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance</article-title>. <source>Cell Metab.</source>
<volume>20</volume>, <fpage>687</fpage>&#x02013;<lpage>695</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2014.09.015</pub-id><?supplied-pmid 25295789?><pub-id pub-id-type="pmid">25295789</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Miguel</surname><given-names>A.</given-names></name><name><surname>Beasley</surname><given-names>C. L.</given-names></name><name><surname>Dwork</surname><given-names>A. J.</given-names></name><name><surname>Mann</surname><given-names>J. J.</given-names></name><name><surname>Rosoklija</surname><given-names>G.</given-names></name><name><surname>Barr</surname><given-names>A. M.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Increased SNARE protein-protein interactions in orbitofrontal and anterior cingulate cortices in schizophrenia</article-title>. <source>Biol. Psychiatry</source>
<volume>78</volume>, <fpage>361</fpage>&#x02013;<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2014.12.012</pub-id><?supplied-pmid 25662103?><pub-id pub-id-type="pmid">25662103</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>M. C.</given-names></name><name><surname>Collins</surname><given-names>P.</given-names></name><name><surname>Thakore</surname><given-names>J. H.</given-names></name></person-group> (<year>2003</year>). <article-title>Impaired fasting glucose tolerance in first-episode, drug na&#x000ef;ve patients with schizophrenia</article-title>. <source>Am. J. Psychiatry</source>
<volume>160</volume>, <fpage>284</fpage>&#x02013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.160.2.284</pub-id><?supplied-pmid 12562574?><pub-id pub-id-type="pmid">12562574</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Chant</surname><given-names>D.</given-names></name><name><surname>Welham</surname><given-names>J.</given-names></name><name><surname>McGrath</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>A systematic review of the prevalence of schizophrenia</article-title>. <source>PLoS Med.</source>
<volume>2</volume>, <fpage>413</fpage>&#x02013;<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.0020141</pub-id><?supplied-pmid 15916472?><pub-id pub-id-type="pmid">15916472</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Involvement of sphingolipids in ethanol neurotoxicity in the developing brain</article-title>. <source>Brain Sci.</source>
<volume>3</volume>, <fpage>670</fpage>&#x02013;<lpage>703</lpage>. <pub-id pub-id-type="doi">10.3390/brainsci3020670</pub-id><?supplied-pmid 24961420?><pub-id pub-id-type="pmid">24961420</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>O.</given-names></name><name><surname>Kobayashi</surname><given-names>A.</given-names></name><name><surname>Nagao</surname><given-names>K.</given-names></name><name><surname>Kumagai</surname><given-names>K.</given-names></name><name><surname>Kioka</surname><given-names>N.</given-names></name><name><surname>Hanada</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1</article-title>. <source>J. Lipid Res.</source>
<volume>48</volume>, <fpage>2377</fpage>&#x02013;<lpage>2384</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M700139-JLR200</pub-id><?supplied-pmid 17761632?><pub-id pub-id-type="pmid">17761632</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Nihei</surname><given-names>Y.</given-names></name><name><surname>Nagafuku</surname><given-names>M.</given-names></name><name><surname>Tagami</surname><given-names>S.</given-names></name><name><surname>Chin</surname><given-names>R.</given-names></name><name><surname>Kawamura</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Circulating levels of ganglioside GM3 in metabolic syndrome: a pilot study</article-title>. <source>Obes. Res. Clin. Pract.</source>
<volume>2</volume>, <fpage>231</fpage>&#x02013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1016/j.orcp.2008.06.001</pub-id><?supplied-pmid 24351849?><pub-id pub-id-type="pmid">24351849</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawai</surname><given-names>H.</given-names></name><name><surname>Hannun</surname><given-names>Y. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Ceramide and sphingomyelinases in the regulation of stress responses</article-title>. <source>Chem. Phys. Lipids</source>
<volume>102</volume>, <fpage>141</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/S0009-3084(99)00082-1</pub-id><?supplied-pmid 11001568?><pub-id pub-id-type="pmid">11001568</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schissel</surname><given-names>S. L.</given-names></name><name><surname>Tweedie-Hardman</surname><given-names>J.</given-names></name><name><surname>Rapp</surname><given-names>J. H.</given-names></name><name><surname>Graham</surname><given-names>G.</given-names></name><name><surname>Williams</surname><given-names>K. J.</given-names></name><name><surname>Tabas</surname><given-names>I.</given-names></name></person-group> (<year>1996</year>). <article-title>Rabbit Aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein: proposed role for arterial-wall sphyngomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins</article-title>. <source>J. Clin. Invest.</source>
<volume>98</volume>, <fpage>1455</fpage>&#x02013;<lpage>1464</lpage>. <pub-id pub-id-type="doi">10.1172/JCI118934</pub-id><?supplied-pmid 8823312?><pub-id pub-id-type="pmid">8823312</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>A.</given-names></name><name><surname>Wilczek</surname><given-names>K.</given-names></name><name><surname>Blennow</surname><given-names>K.</given-names></name><name><surname>Maras</surname><given-names>A.</given-names></name><name><surname>Jatzko</surname><given-names>A.</given-names></name><name><surname>Petroianu</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Altered thalamic membrane phospholipids in schizophrenia: a postmortem study</article-title>. <source>Biol. Psychiatry</source>
<volume>56</volume>, <fpage>41</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2004.03.019</pub-id><?supplied-pmid 15219471?><pub-id pub-id-type="pmid">15219471</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>E.</given-names></name><name><surname>Prabakaran</surname><given-names>S.</given-names></name><name><surname>Whitfield</surname><given-names>P.</given-names></name><name><surname>Major</surname><given-names>H.</given-names></name><name><surname>Leweke</surname><given-names>F. M.</given-names></name><name><surname>Keothe</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>High troughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcolines and ceramides</article-title>. <source>J. Proteome Res.</source>
<volume>7</volume>, <fpage>4266</fpage>&#x02013;<lpage>4277</lpage>. <pub-id pub-id-type="doi">10.1021/pr800188y</pub-id><?supplied-pmid 18778095?><pub-id pub-id-type="pmid">18778095</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seshadri</surname><given-names>S.</given-names></name><name><surname>Zeledon</surname><given-names>M.</given-names></name><name><surname>Sawa</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Synapse-specific contributions in the cortical pathology of schizophrenia</article-title>. <source>Neurobiol. Dis.</source>
<volume>53</volume>, <fpage>26</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2013.01.009</pub-id><?supplied-pmid 23336981?><pub-id pub-id-type="pmid">23336981</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimabukuro</surname><given-names>M.</given-names></name><name><surname>Higa</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>Y. T.</given-names></name><name><surname>Wang</surname><given-names>M. Y.</given-names></name><name><surname>Newgard</surname><given-names>C. B.</given-names></name><name><surname>Unger</surname><given-names>R. H.</given-names></name></person-group> (<year>1998a</year>). <article-title>Lipoapoptosis in beta-cells of obese prediabetic <italic>fa/fa</italic> rats. Role of serine palmitoyltransferase overexpression</article-title>. <source>J. Biol. Chem.</source>
<volume>273</volume>, <fpage>32487</fpage>&#x02013;<lpage>32490</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.273.49.32487</pub-id><?supplied-pmid 9829981?><pub-id pub-id-type="pmid">9829981</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimabukuro</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>Y. T.</given-names></name><name><surname>Levi</surname><given-names>M.</given-names></name><name><surname>Unger</surname><given-names>R. H.</given-names></name></person-group> (<year>1998b</year>). <article-title>Fatty acid-induced b cell apoptosis: a link between obesity and diabetes</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>95</volume>, <fpage>2498</fpage>&#x02013;<lpage>2502</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.5.2498</pub-id><?supplied-pmid 9482914?><pub-id pub-id-type="pmid">9482914</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smesny</surname><given-names>S.</given-names></name><name><surname>Schmelzer</surname><given-names>C. E.</given-names></name><name><surname>Hinder</surname><given-names>A.</given-names></name><name><surname>K&#x000f6;hler</surname><given-names>A.</given-names></name><name><surname>Schneider</surname><given-names>C.</given-names></name><name><surname>Rudzok</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Skin ceramide alterations in first-episode schizophrenia indicate abnormal sphingolipid metabolism</article-title>. <source>Schizophr. Bull.</source>
<volume>39</volume>, <fpage>933</fpage>&#x02013;<lpage>941</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbs058</pub-id><?supplied-pmid 22589371?><pub-id pub-id-type="pmid">22589371</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soeda</surname><given-names>S.</given-names></name><name><surname>Honda</surname><given-names>O.</given-names></name><name><surname>Shimeno</surname><given-names>H.</given-names></name><name><surname>Nagamatsu</surname><given-names>A.</given-names></name></person-group> (<year>1995</year>). <article-title>Sphingomyelinase and cell-permeable ceramide analogs increase the release of plasminogen activator inhibitor-1 from cultured endothelial cells</article-title>. <source>Thromb. Res.</source>
<volume>80</volume>, <fpage>509</fpage>&#x02013;<lpage>518</lpage>. <?supplied-pmid 8610279?><pub-id pub-id-type="pmid">8610279</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spelman</surname><given-names>L. M.</given-names></name><name><surname>Walsh</surname><given-names>P. I.</given-names></name><name><surname>Sharifi</surname><given-names>N.</given-names></name><name><surname>Collins</surname><given-names>P.</given-names></name><name><surname>Thakore</surname><given-names>J. H.</given-names></name></person-group> (<year>2007</year>). <article-title>Impaired glucose tolerance in first-episode drug-na&#x000ef;ve patients with schizophrenia</article-title>. <source>Diabet. Med.</source>
<volume>24</volume>, <fpage>481</fpage>&#x02013;<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-5491.2007.02092.x</pub-id><?supplied-pmid 17381506?><pub-id pub-id-type="pmid">17381506</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srihari</surname><given-names>V. H.</given-names></name><name><surname>Puhutane</surname><given-names>V. H.</given-names></name><name><surname>Ozkan</surname><given-names>B.</given-names></name><name><surname>Chwastiak</surname><given-names>L.</given-names></name><name><surname>Ratliff</surname><given-names>J. C.</given-names></name><name><surname>Woods</surname><given-names>S. W.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Cardiovascular mortality in schizophrenia: defining a critical period for prevention</article-title>. <source>Schizophr. Res.</source>
<volume>146</volume>, <fpage>64</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2013.01.014</pub-id><?supplied-pmid 23422728?><pub-id pub-id-type="pmid">23422728</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephan</surname><given-names>K. E.</given-names></name><name><surname>Baldeweg</surname><given-names>T.</given-names></name><name><surname>Friston</surname><given-names>K. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Synaptic plasticity and dysconnection in schizophrenia</article-title>. <source>Biol. Psychiatry</source>
<volume>5</volume>, <fpage>929</fpage>&#x02013;<lpage>939</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.10.005</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephan</surname><given-names>K. E.</given-names></name><name><surname>Friston</surname><given-names>K. J.</given-names></name><name><surname>Frith</surname><given-names>C. D.</given-names></name></person-group> (<year>2009</year>). <article-title>Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring</article-title>. <source>Schizophr. Bull.</source>
<volume>35</volume>, <fpage>509</fpage>&#x02013;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbn176</pub-id><?supplied-pmid 19155345?><pub-id pub-id-type="pmid">19155345</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straczkowski</surname><given-names>M.</given-names></name><name><surname>Kowalska</surname><given-names>I.</given-names></name><name><surname>Baranowski</surname><given-names>M.</given-names></name><name><surname>Nikolajuk</surname><given-names>A.</given-names></name><name><surname>Otziomek</surname><given-names>E.</given-names></name><name><surname>Zabielski</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes</article-title>. <source>Diabetologia</source>
<volume>50</volume>, <fpage>2366</fpage>&#x02013;<lpage>2377</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-007-0781-2</pub-id><?supplied-pmid 17724577?><pub-id pub-id-type="pmid">17724577</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratford</surname><given-names>S.</given-names></name><name><surname>DeWald</surname><given-names>D. B.</given-names></name><name><surname>Summers</surname><given-names>S. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Ceramide dissociates 3&#x02032;-phosphoinositide production from pleckstrin homology domain translocation</article-title>. <source>Biochem. J.</source>
<volume>354</volume>, <fpage>359</fpage>&#x02013;<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1042/bj3540359</pub-id><?supplied-pmid 11171115?><pub-id pub-id-type="pmid">11171115</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>H. S.</given-names></name></person-group> (<year>1994</year>). <article-title>The onset of schizophrenia. 1927</article-title>. <source>Am. J. Psychiatry</source>
<volume>151</volume>, <fpage>134</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.84.1.105</pub-id><?supplied-pmid 8192188?><pub-id pub-id-type="pmid">8192188</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Summers</surname><given-names>S. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Ceramides in insulin resistance and lipotoxicity</article-title>. <source>Prog. Lipid Res.</source>
<volume>45</volume>, <fpage>42</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.plipres.2005.11.002</pub-id><?supplied-pmid 16445986?><pub-id pub-id-type="pmid">16445986</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagami</surname><given-names>S.</given-names></name><name><surname>Inokuchi</surname><given-names>J.-I.</given-names></name><name><surname>Kabayama</surname><given-names>K.</given-names></name><name><surname>Yoshimura</surname><given-names>H.</given-names></name><name><surname>Kitamura</surname><given-names>F.</given-names></name><name><surname>Uemura</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Ganglioside GM3 participates in the pathological conditions of insulin resistance</article-title>. <source>J. Biol. Chem.</source>
<volume>277</volume>, <fpage>3085</fpage>&#x02013;<lpage>3092</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M103705200</pub-id><?supplied-pmid 11707432?><pub-id pub-id-type="pmid">11707432</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tkachev</surname><given-names>D.</given-names></name><name><surname>Mimmack</surname><given-names>M. L.</given-names></name><name><surname>Ryan</surname><given-names>M. M.</given-names></name><name><surname>Wayland</surname><given-names>M.</given-names></name><name><surname>Freeman</surname><given-names>T.</given-names></name><name><surname>Jones</surname><given-names>P. B.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Oligodendrocyte dysfunction in schizophrenia and bipolar disorder</article-title>. <source>Lancet</source>
<volume>362</volume>, <fpage>798</fpage>&#x02013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)14289-4</pub-id><?supplied-pmid 13678875?><pub-id pub-id-type="pmid">13678875</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turpin</surname><given-names>S. M.</given-names></name><name><surname>Nicholls</surname><given-names>H. T.</given-names></name><name><surname>Willmes</surname><given-names>D. M.</given-names></name><name><surname>Mourier</surname><given-names>A.</given-names></name><name><surname>Brodesser</surname><given-names>S.</given-names></name><name><surname>Wunderlich</surname><given-names>C. M.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance</article-title>. <source>Cell Metab.</source>
<volume>20</volume>, <fpage>678</fpage>&#x02013;<lpage>686</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2014.08.002</pub-id><?supplied-pmid 25295788?><pub-id pub-id-type="pmid">25295788</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlhaas</surname><given-names>P. J.</given-names></name><name><surname>Singer</surname><given-names>W.</given-names></name></person-group> (<year>2010</year>). <article-title>Abnormal neural oscillations and synchrony in schizophrenia</article-title>. <source>Nat. Rev. Neurosci.</source>
<volume>11</volume>, <fpage>100</fpage>&#x02013;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2774</pub-id><?supplied-pmid 20087360?><pub-id pub-id-type="pmid">20087360</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unger</surname><given-names>R. H.</given-names></name><name><surname>Orci</surname><given-names>L.</given-names></name></person-group> (<year>2002</year>). <article-title>Lipoapoptosis: its mechanism and its diseases</article-title>. <source>Biochem. Biophys. Acta</source>
<volume>1585</volume>, <fpage>202</fpage>&#x02013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/S1388-1981(02)00342-6</pub-id><?supplied-pmid 12531555?><pub-id pub-id-type="pmid">12531555</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Echten-Deckert</surname><given-names>G.</given-names></name><name><surname>Herget</surname><given-names>T.</given-names></name></person-group> (<year>2006</year>). <article-title>Sphingolipid metabolism in neural cells</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1758</volume>, <fpage>1978</fpage>&#x02013;<lpage>1994</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2006.06.009</pub-id><?supplied-pmid 16843432?><pub-id pub-id-type="pmid">16843432</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veillon</surname><given-names>L.</given-names></name><name><surname>Go</surname><given-names>S.</given-names></name><name><surname>Matsuyama</surname><given-names>W.</given-names></name><name><surname>Suzuki</surname><given-names>A.</given-names></name><name><surname>Nagasaki</surname><given-names>M.</given-names></name><name><surname>Yatomi</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Identification of ganglioside GM3 molecular species in human serum associated with risk factors of metabolic syndrome</article-title>. <source>PLoS ONE</source>
<volume>10</volume>:<fpage>e0129645</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0129645</pub-id><?supplied-pmid 26102277?><pub-id pub-id-type="pmid">26102277</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S. K.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Liew</surname><given-names>A.</given-names></name><name><surname>Poon</surname><given-names>L. Y.</given-names></name></person-group> (<year>2009</year>). <article-title>Metabolic risk factors in drug-na&#x000ef;ve patients with first-episode psychosis</article-title>. <source>J. Clin. Psychiatry</source>
<volume>70</volume>, <fpage>997</fpage>&#x02013;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.4088/JCP.08m04508</pub-id><?supplied-pmid 19497246?><pub-id pub-id-type="pmid">19497246</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weickert</surname><given-names>C. S.</given-names></name><name><surname>Weickert</surname><given-names>T. W.</given-names></name><name><surname>Pillai</surname><given-names>A.</given-names></name><name><surname>Buckley</surname><given-names>P. F.</given-names></name></person-group> (<year>2013</year>). <article-title>Biomarkers in schizophrenia: a brief conceptual consideration</article-title>. <source>Dis. Markers</source>
<volume>35</volume>, <fpage>3</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1155/2013/510402</pub-id><?supplied-pmid 24167344?><pub-id pub-id-type="pmid">24167344</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2001</year>). <source>Mental Health: New Understanding, New Hope</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodward</surname><given-names>N. D.</given-names></name><name><surname>Karbasforoushan</surname><given-names>H.</given-names></name><name><surname>Heckers</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Thalamocortical dysconnectivity in schizophrenia</article-title>. <source>Am. J. Psychiatry</source>
<volume>169</volume>, <fpage>1092</fpage>&#x02013;<lpage>1099</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2012.12010056</pub-id><?supplied-pmid 23032387?><pub-id pub-id-type="pmid">23032387</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worgall</surname><given-names>T. S.</given-names></name></person-group> (<year>2008</year>). <article-title>Regulation of lipid metabolism by sphingolipids</article-title>. <source>Subcell. Biochem.</source>
<volume>49</volume>, <fpage>371</fpage>&#x02013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4020-8830-8_14</pub-id><?supplied-pmid 18751919?><pub-id pub-id-type="pmid">18751919</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worgall</surname><given-names>T. S.</given-names></name><name><surname>Johnson</surname><given-names>R. A.</given-names></name><name><surname>Seo</surname><given-names>T.</given-names></name><name><surname>Gierens</surname><given-names>H.</given-names></name><name><surname>Deckelbaum</surname><given-names>R. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Unsaturated fatty acid-mediated decreases in sterol regulatory element-mediated gene transcription are linked to cellular sphingolipid metabolism</article-title>. <source>J. Biol. Chem.</source>
<volume>277</volume>, <fpage>3878</fpage>&#x02013;<lpage>3885</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M102393200</pub-id><?supplied-pmid 11707431?><pub-id pub-id-type="pmid">11707431</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J. K.</given-names></name><name><surname>Leonard</surname><given-names>S.</given-names></name><name><surname>Reddy</surname><given-names>R. D.</given-names></name></person-group> (<year>2000</year>). <article-title>Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients</article-title>. <source>Schizophr. Res.</source>
<volume>42</volume>, <fpage>7</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/S0920-9964(99)00095-X</pub-id><?supplied-pmid 10706981?><pub-id pub-id-type="pmid">10706981</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaqoob</surname><given-names>P.</given-names></name><name><surname>Shaikh</surname><given-names>S. R.</given-names></name></person-group> (<year>2010</year>). <article-title>The nutritional and clinical significance of lipid rafts</article-title>. <source>Curr. Opin. Clin. Nutr. Metab. Care</source>
<volume>13</volume>, <fpage>156</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1097/MCO.0b013e328335725b</pub-id><?supplied-pmid 20010096?><pub-id pub-id-type="pmid">20010096</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yogaratnam</surname><given-names>J., Biswas, N.</given-names></name><name><surname>Vadivel</surname><given-names>R.</given-names></name><name><surname>Jacob</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Metabolic complications of schizophrenia and antipsychotic medications&#x02013;an updated review</article-title>. <source>East Asian Arch. Psychiatry</source>
<volume>23</volume>, <fpage>21</fpage>&#x02013;<lpage>28</lpage>. <?supplied-pmid 23535629?><pub-id pub-id-type="pmid">23535629</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeidan</surname><given-names>Y. H.</given-names></name><name><surname>Hannun</surname><given-names>Y. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Translational aspects of sphingolipid metabolism</article-title>. <source>Trends Mol. Med.</source>
<volume>13</volume>, <fpage>327</fpage>&#x02013;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2007.06.002</pub-id><?supplied-pmid 17588815?><pub-id pub-id-type="pmid">17588815</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinda</surname><given-names>M. J.</given-names></name><name><surname>Vlahos</surname><given-names>C. J.</given-names></name><name><surname>Lai</surname><given-names>M. T.</given-names></name></person-group> (<year>2001</year>). <article-title>Ceramide induces the dephosphorilation and inhibition of constitutively activated Akt in PTEN negative U87mg cells</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>280</volume>, <fpage>1107</fpage>&#x02013;<lpage>1115</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.2000.4248</pub-id><?supplied-pmid 11162641?><pub-id pub-id-type="pmid">11162641</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Z&#x000f6;ller</surname><given-names>I.</given-names></name><name><surname>B&#x000fc;ssow</surname><given-names>H.</given-names></name><name><surname>Gieselmann</surname><given-names>V.</given-names></name><name><surname>Eckhardt</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>Oligodendrocyte-specific ceramide galactosyltransferase (CGT) expression phenotypically rescues CGT-deficient mice and demonstrates that CGT activity does not limit brain galactosylceramide level</article-title>. <source>Glia</source>
<volume>52</volume>, <fpage>190</fpage>&#x02013;<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1002/glia.20230</pub-id><?supplied-pmid 15968630?><pub-id pub-id-type="pmid">15968630</pub-id></mixed-citation></ref></ref-list><app-group><app><title>Nomenclature</title><p>ADRA1A = Alpha-1A adrenergic receptor</p><p>Akt/PKB = Protein Kinase B</p><p>BDNF = Brain-derived neurotrophic factor</p><p>CerS = Ceramide Synthase</p><p>CGT = Galactosyltransferase</p><p>CNS = Central Nervous System</p><p>CST = Cerebroside Sulfotransferase</p><p>DHA = Docosahexaenoic acid</p><p>DTI = Diffusion Tensor Imaging</p><p>EEG = Electroencephalogram</p><p>EPA = Eicosapentaenoic acid</p><p>FFAs = Free Fatty Acids</p><p>fMRI = Functional Magnetic Resonance Imaging</p><p>GABA = Gamma-Aminobutyric Acid</p><p>GLUT-4 = Glucose Transporter Type 4</p><p>GSLs = Glycosphingolipids</p><p>HDL = High Density Lipoprotein</p><p>IRS-1 = Insulin Receptor Substrate-1</p><p>I&#x003ba;K&#x003b2; = Inhibitor of kappa B Kinase beta</p><p>JNK = c-Jun N-Terminal Kinases</p><p>LDL = Low Density Lipoprotein</p><p>MS = Metabolic Syndrome</p><p>MTHFR = Methylenetetrahydrofolate Reductase</p><p>NMDA = N-methyl-D-aspartate</p><p>PAI-1 = Plasminogen Activator Inhibitor-1</p><p>PC = Phosphatidylcholine</p><p>PI3K = Phosphoinositide 3-kinase</p><p>PKC&#x003b6; = Protein Kinase C zeta</p><p>PP2A = Protein Phosphatase 2A</p><p>PUFAs = Polyunsaturated fatty acids</p><p>S1P = Sphingosine-1-Phosphate</p><p>SFAs = Saturated Fatty Acids</p><p>SLs = Sphingolipids</p><p>SMs = Sphingomyelins</p><p>SREBPs = Sterol-Regulatory Element Binding Proteins</p><p>SZ = Schizophrenia</p><p>TNF-&#x003b1; = Tumor Necrosis Factor &#x003b1;</p></app></app-group></back></article>